Diagnostic drugs and methods for Alzheimer's disease
By detecting short and long fragments of S38AA peptides and their antibodies, the problem of insufficient sensitivity in the early diagnosis of Alzheimer's disease in existing technologies has been solved, enabling accurate assessment of the disease status and support for personalized treatment.
Patent Information
- Application Number
- CN201980052567.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-08-07
- Filing Date
- 2019-08-06
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-08-06
AI Technical Summary
Current technologies are insufficient to accurately determine the onset and risk of Alzheimer's disease, and the accuracy of early diagnostic biomarkers is inadequate, affecting the effectiveness of treatment.
Using short and long fragments of S38AA peptides and their specific antibodies, reagents and methods for determining Alzheimer's disease can be developed by detecting the amount of peptides in blood or cerebrospinal fluid, including quantifying and comparing peptide levels to assess disease status.
It provides a highly reliable method to accurately determine the onset and progression of Alzheimer's disease, identify disease risk early, and support personalized treatment decisions.
Smart Images

Figure 4129 
Figure 107469 
Figure 116572
Abstract
Description
[Technical field]
[0002] The present invention relates to an agent for determining Alzheimer's disease, a method for determining Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening candidate substances for therapeutic drugs for Alzheimer's disease, a novel anti-S38AA antibody, and the like. [Background Technology]
[0004] Alzheimer's disease is a progressive dementia, which begins with the decline of short-term memory and mild learning disability, develops higher brain dysfunction, especially visual spatial agnosia, conceptual apraxia, structural apraxia, etc., and eventually reaches movement disorders and so-called personality destruction, and no radical treatment method has been found so far. It is estimated that in 2040, there will be 2.4 million patients with Alzheimer's disease in the world, and the importance of radical treatment methods or its early diagnosis is increasing. Its progress is different from the vascular dementia often found in Japan, and it is considered to last for several years to ten years or longer. In the case of patients with familial Alzheimer's disease (which is one of Alzheimer's disease) caused by abnormal gene mutation, the conditions of many patients deteriorate rapidly in a few years, and the disease is characterized by early onset, because the age at the time of onset is 30-40 years old. In addition to gene mutation, age, family history, genotype, hypertension, diabetes, smoking, etc. are known as risk factors for Alzheimer's disease.
[0005] As characteristic pathological changes in Alzheimer's disease, it is widely known that the extracellular accumulation of amyloid plaques containing amyloid beta as the main component and the accumulation of highly phosphorylated tau protein in nerve cells occur. As for the spatiotemporal pathological changes in the brain, since the accumulation of phosphorylated tau in the pyramidal cells in the hippocampus (especially the region called CA1) has been observed in patients with early onset Alzheimer's disease, the pyramidal cells in this region are considered to be exposed to the strong influence of Alzheimer's disease in space and time at an early stage, i.e., show vulnerability (non-patent literature 2). On the other hand, since dyskinesia almost occurs in the final stage of Alzheimer's disease as described above, the Purkinje cells in the cerebellum are considered to be the most resistant to Alzheimer's disease.
[0006] It is believed that the incidence of Alzheimer's disease increases rapidly after the age of 75, and early detection and early initiation of treatment are important for inhibiting pathological progression by symptomatic drug therapy. Since there is currently no radical cure for Alzheimer's disease, diagnostic markers for early detection of Alzheimer's disease are actively sought, and amyloid β (Aβ40, Aβ42) and phosphorylated tau protein measurements in blood or cerebrospinal fluid are considered to be the most promising. However, even when these markers (e.g., the ratio of Aβ40 to Aβ42) are used alone or in combination, it is still difficult to clearly find the acquisition of Alzheimer's disease (i.e., potential patients with Alzheimer's disease) in the future.
[0007] On the other hand, S38AA, particularly its extracellular domain, has been reported as a diagnostic marker for Alzheimer's disease (Patent Document 1).
[0008] However, since early detection and early initiation of treatment are important for Alzheimer's disease, a method capable of determining the onset of Alzheimer's disease and persons at risk of Alzheimer's disease with higher sensitivity has been needed.
[0009] [File list]
[0010] [Patent document]
[0011] Patent document 1: WO 2012 / 091138
[0012] [Non-patent document]
[0013] Non-patent document 1: Exp Gerontol. (2000) 35: 851-64. [Summary of the Invention]
[0015] [Technical issues]
[0016] The present invention aims to provide a reagent for determining Alzheimer's disease, a method for determining Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening candidate substances for therapeutic drugs for Alzheimer's disease, and the like.
[0017] [Solution to the problem]
[0018] It is known that the S38AA fragment increases in the cerebrospinal fluid and plasma of Alzheimer's disease patients (hereinafter sometimes referred to as "AD patients"). The present inventors have discovered two S38AA fragments (S38AA short fragment (hereinafter sometimes referred to as "short fragment") and S38AA long fragment (hereinafter sometimes referred to as "long fragment") that have a particularly high correlation with Alzheimer's disease. The present inventors have further conducted intensive studies and found that the S38AA short fragment has extremely high reliability as an indicator for highly accurately determining the onset of Alzheimer's disease and people at risk of Alzheimer's disease and the degree of progression of the disease, which led to the completion of the present invention.
[0019] That is, the present invention relates to the following contents.
[0020] [1] A polypeptide consisting of any of the following amino acid sequences:
[0021] (1) the amino acid sequence shown in SEQ ID NO: 1; and
[0022] (2) An amino acid sequence produced by substitution, deletion, addition or insertion of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 1.
[0023] [2] An antibody that specifically recognizes the polypeptide of [1].
[0024] [3] A nucleic acid encoding the polypeptide of [1].
[0025] [4] A kit comprising the antibody of [2].
[0026] [5] The kit of [4], further comprising the polypeptide of [1].
[0027] [6] A method for detecting the polypeptide of [1], comprising the step of contacting a test sample with the antibody of [2].
[0028] [7] The kit of [4] or [5], which is used for determining Alzheimer's disease.
[0029] [8] A reagent for determining Alzheimer's disease, comprising one or more anti-S38AA antibodies capable of measuring the amount of the polypeptide of [1].
[0030] [9] The reagent of [8], wherein the anti-S38AA antibody is the antibody of [2].
[0031]
[10] Use of the antibody of [2] for preparing a reagent for determining Alzheimer's disease.
[0032]
[11] A method for determining the likelihood that a test animal currently suffers from Alzheimer's disease or that the animal may suffer from Alzheimer's disease in the future, comprising detecting the polypeptide of [1] in a sample collected from the animal.
[0033]
[12] The method of
[11] , comprising the following steps (i) to (iii):
[0034] (i) a step of quantifying the polypeptide of [1] in a sample collected from a test animal,
[0035] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from a healthy animal (hereinafter referred to as a control value), and
[0036] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the aforementioned control value, the step of determining that the aforementioned test animal may currently suffer from Alzheimer's disease or the animal may suffer from Alzheimer's disease in the future.
[0037]
[13] A method for assisting in determining the progression of Alzheimer's disease, comprising the following steps (i) to (iii):
[0038] (i) a step of quantifying the polypeptide of [1] in a sample collected from a test animal suffering from or likely to suffer from Alzheimer's disease,
[0039] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from the test animal in the past (hereinafter referred to as a control value), and
[0040] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the control value, determining that Alzheimer's disease in the aforementioned test animal is progressing, and when the amount is lower than the control value, determining that Alzheimer's disease in the aforementioned test animal is improving.
[0041]
[14] The method of any one of
[11] to
[13] , wherein the test animal is a human.
[0042]
[15] The method of any one of
[11] to
[14] , wherein the sample is blood, cerebrospinal fluid, saliva, tears or urine.
[0043]
[16] The method of any one of
[11] to
[15] , further comprising detecting one or more other Alzheimer's disease diagnostic markers.
[0044]
[17] A method for treating or preventing Alzheimer's disease, comprising the following steps (i) to (iv):
[0045] (i) a step of quantifying the polypeptide of [1] in a sample collected from a test animal,
[0046] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from a healthy animal (hereinafter referred to as a control value),
[0047] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the aforementioned control value, a step of determining that the aforementioned test animal currently suffers from or is likely to suffer from Alzheimer's disease or that the animal is likely to suffer from Alzheimer's disease in the future, and
[0048] (iv) a step of administering a therapeutic or preventive drug for Alzheimer's disease to the test animal determined to currently suffer from or likely suffer from Alzheimer's disease or likely suffer from Alzheimer's disease in the future based on the result of (iii).
[0049]
[18] A method for treating or preventing Alzheimer's disease, comprising the following steps (i) to (v):
[0050] (i) a step of quantifying the polypeptide of [1] in a sample collected from a test animal currently suffering from or likely to suffer from Alzheimer's disease,
[0051] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from the test animal in the past (hereinafter referred to as a control value),
[0052] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the control value, determining that the Alzheimer's disease in the aforementioned test animal is progressing, and when the amount is lower than the control value, determining that the Alzheimer's disease in the aforementioned test animal is improving,
[0053] (iv) a step of selecting a therapeutic or preventive drug for Alzheimer's disease based on the result of (iii), and
[0054] (v) a step of administering the therapeutic drug for Alzheimer's disease selected in (iv) to the test animal.
[0055]
[19] The method of
[17] or
[18] , wherein the therapeutic drug for Alzheimer's disease is selected from cholinesterase inhibitors, NMDA receptor antagonists, amyloid β removers and accumulation inhibitors, and tau protein removers and accumulation inhibitors.
[0056]
[20] The method of
[19] , wherein the cholinesterase inhibitor is donepezil, galantamine, rivastigmine, huperzine A or tacrine, and the NMDA receptor antagonist is memantine.
[0057]
[21] A therapeutic agent for use in a patient with Alzheimer's disease, wherein the progression of the patient's Alzheimer's disease is determined by the following steps (i)-(iv):
[0058] (i) a step of quantifying the polypeptide of [1] in a sample collected from a test animal currently suffering from or likely to suffer from Alzheimer's disease,
[0059] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from the test animal in the past (hereinafter referred to as a control value),
[0060] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the control value, determining that Alzheimer's disease in the aforementioned test animal is progressing, and when the amount is lower than the control value, determining that Alzheimer's disease in the aforementioned test animal is improving, and
[0061] (iv) a step of selecting a therapeutic or preventive drug for Alzheimer's disease based on the result of (iii).
[0062]
[22] A therapeutic or preventive drug for Alzheimer's disease, comprising as an active ingredient: a drug that reduces the amount of the polypeptide of [1] in the body of a patient with Alzheimer's disease or a person who may suffer from Alzheimer's disease, or a drug that inhibits the production of the polypeptide in the body of a patient with Alzheimer's disease or a person who may suffer from Alzheimer's disease.
[0063]
[23] A method for screening candidate substances for therapeutic or preventive drugs for Alzheimer's disease, comprising using as an indicator: a decrease in the amount of a polypeptide of [1] in the body of an Alzheimer's disease patient or a person who may be suffering from Alzheimer's disease, or an inhibition of the production of the polypeptide in the body of an Alzheimer's disease patient or a person who may be suffering from Alzheimer's disease.
[0064]
[24] An antibody that recognizes the polypeptide of SEQ ID NO: 1 or 2, comprising:
[0065] A heavy chain variable region having an amino acid sequence that is at least 95% homologous to:
[0066] SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, or SEQ ID NO:22, and
[0067] A light chain variable region having an amino acid sequence that is at least 95% homologous to:
[0068] SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21 or SEQ ID NO:23.
[0069]
[25] An antibody that recognizes the polypeptide of SEQ ID NO: 1 or 2, comprising:
[0070] (1) a heavy chain variable region of SEQ ID NO: 4, and a light chain variable region of SEQ ID NO: 5,
[0071] (2) a heavy chain variable region of SEQ ID NO: 6, and a light chain variable region of SEQ ID NO: 7,
[0072] (3) a heavy chain variable region of SEQ ID NO: 8, and a light chain variable region of SEQ ID NO: 9,
[0073] (4) a heavy chain variable region of SEQ ID NO: 10, and a light chain variable region of SEQ ID NO: 11,
[0074] (5) a heavy chain variable region of SEQ ID NO: 12, and a light chain variable region of SEQ ID NO: 13,
[0075] (6) a heavy chain variable region of SEQ ID NO: 14, and a light chain variable region of SEQ ID NO: 15,
[0076] (7) a heavy chain variable region of SEQ ID NO: 16, and a light chain variable region of SEQ ID NO: 17,
[0077] (8) a heavy chain variable region of SEQ ID NO: 18, and a light chain variable region of SEQ ID NO: 19,
[0078] (9) the heavy chain variable region of SEQ ID NO: 20, and the light chain variable region of SEQ ID NO: 21, or
[0079] (10) the heavy chain variable region of SEQ ID NO:22, and the light chain variable region of SEQ ID NO:23.
[0080]
[26] A kit comprising the antibody of
[24] or
[25] .
[0081]
[27] The kit of
[26] , further comprising the polypeptide of SEQ ID NO:1.
[0082]
[28] A method for detecting the polypeptide of SEQ ID NO: 1, comprising the step of contacting a test sample with the antibody of
[24] or
[25] .
[0083]
[29] The kit of
[26] or
[27] , which is used for determining Alzheimer's disease.
[0084]
[30] A reagent for determining Alzheimer's disease, comprising the antibody of
[24] or
[25] capable of measuring the amount of the polypeptide of SEQ ID NO:1.
[0085]
[31] A method for determining the likelihood that a test animal currently suffers from Alzheimer's disease or that the animal may suffer from Alzheimer's disease in the future, comprising detecting the polypeptide of SEQ ID NO: 1 in a sample collected from the animal by using the antibody of
[24] or
[25] .
[0086]
[32] The method of
[31] , comprising the following steps (i) to (iii):
[0087] (i) a step of quantifying the polypeptide of SEQ ID NO: 1 in a sample collected from a test animal by using the antibody of
[24] or
[25] ,
[0088] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from a healthy animal (hereinafter referred to as a control value), and
[0089] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the aforementioned control value, the step of determining that the aforementioned test animal may currently suffer from Alzheimer's disease or the animal may suffer from Alzheimer's disease in the future.
[0090]
[33] A method for determining the progression of Alzheimer's disease, comprising the following steps (i) to (iii):
[0091] (i) a step of quantifying the polypeptide of claim 1 in a sample collected from a test animal suffering from or likely to suffer from Alzheimer's disease by using the antibody of
[24] or
[25] ,
[0092] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from the test animal in the past (hereinafter referred to as a control value), and
[0093] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the control value, determining that Alzheimer's disease in the aforementioned test animal is progressing, and when the amount is lower than the control value, determining that Alzheimer's disease in the aforementioned test animal is improving.
[0094]
[34] The method of any one of
[31] to
[33] , wherein the test animal is a human.
[0095]
[35] The method of any one of
[31] to
[34] , wherein the sample is blood, cerebrospinal fluid, saliva, tears or urine.
[0096]
[36] The method of any one of
[31] to
[35] , further comprising detecting one or more other Alzheimer's disease diagnostic markers.
[0097]
[37] A method for treating Alzheimer's disease, comprising administering a therapeutic drug for Alzheimer's disease to a patient with confirmed progression of Alzheimer's disease, the method comprising the following steps (i)-(iv):
[0098] (i) a step of quantifying the polypeptide of SEQ ID NO: 1 in a sample collected from a test animal suffering from or likely to suffer from Alzheimer's disease by using the antibody of any one of
[24] and
[25] ,
[0099] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from the test animal in the past (hereinafter referred to as a control value), and
[0100] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the control value, determining that Alzheimer's disease in the aforementioned test animal is progressing, and when the amount is lower than the control value, determining that Alzheimer's disease in the aforementioned test animal is improving, and
[0101] (iv) Based on the result of (iii), a step of administering a therapeutic drug for Alzheimer's disease to a test animal in need thereof.
[0102]
[38] A method for treating or preventing Alzheimer's disease, comprising as an active ingredient: a drug that reduces the amount of the polypeptide of SEQ ID NO: 1 in the body of an Alzheimer's disease patient diagnosed using the antibody of any one of
[24] and
[25] or a person who may have Alzheimer's disease, or a drug that inhibits the production of the polypeptide in the body of the aforementioned Alzheimer's disease patient or the aforementioned person who may have Alzheimer's disease.
[0103]
[39] A method for screening candidate substances for therapeutic or preventive drugs for Alzheimer's disease by using the antibody of any one of
[24] and
[25] , comprising using as an indicator: a decrease in the amount of the polypeptide of SEQ ID NO: 1 in the body of an Alzheimer's disease patient or a person who may suffer from Alzheimer's disease, or an inhibition of the production of the polypeptide in the body of an Alzheimer's disease patient or a person who may suffer from Alzheimer's disease.
[0104] [Item 1] A polypeptide consisting of any of the following amino acid sequences:
[0105] (1) the amino acid sequence shown in SEQ ID NO: 1; and
[0106] (2) An amino acid sequence produced by substitution, deletion, addition or insertion of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 1.
[0107] [Item 2] The polypeptide of Item 1, which consists of the amino acid sequence shown in SEQ ID NO: 1.
[0108] [Item 3] A nucleic acid encoding the polypeptide of Item 1 or 2.
[0109] [Item 4] An antibody that recognizes the polypeptide of Item 1 or 2.
[0110] [Item 5] The antibody of Item 4, which further recognizes the polypeptide of SEQ ID NO: 2.
[0111] [Item 6] The antibody of Item 4 or 5, comprising:
[0112] A heavy chain variable region having an amino acid sequence that is at least 95% homologous to:
[0113] SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, or SEQ ID NO:22, and
[0114] A light chain variable region having an amino acid sequence that is at least 95% homologous to:
[0115] SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21 or SEQ ID NO:23.
[0116] [Item 7] The antibody according to any one of Items 4 to 6, comprising:
[0117] A heavy chain variable region having an amino acid sequence that is at least 99% homologous to:
[0118] SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, or SEQ ID NO:22, and
[0119] A light chain variable region having an amino acid sequence that is at least 99% homologous to:
[0120] SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21 or SEQ ID NO:23.
[0121] [Item 8] The antibody of any one of Items 4 to 6, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20 or SEQ ID NO: 22, and
[0122] The amino acid sequence of the light chain variable region is SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21 or SEQ ID NO:23.
[0123] [Item 9] The antibody of any one of Items 4 to 8, wherein the antibody is
[0124] (1) an antibody comprising a heavy chain variable region of SEQ ID NO: 4 and a light chain variable region of SEQ ID NO: 5,
[0125] (2) an antibody comprising a heavy chain variable region of SEQ ID NO: 6 and a light chain variable region of SEQ ID NO: 7,
[0126] (3) an antibody comprising a heavy chain variable region of SEQ ID NO: 8 and a light chain variable region of SEQ ID NO: 9,
[0127] (4) an antibody comprising a heavy chain variable region of SEQ ID NO: 10 and a light chain variable region of SEQ ID NO: 11,
[0128] (5) an antibody comprising a heavy chain variable region of SEQ ID NO: 12 and a light chain variable region of SEQ ID NO: 13,
[0129] (6) an antibody comprising a heavy chain variable region of SEQ ID NO: 14 and a light chain variable region of SEQ ID NO: 15,
[0130] (7) an antibody comprising a heavy chain variable region of SEQ ID NO: 16 and a light chain variable region of SEQ ID NO: 17,
[0131] (8) an antibody comprising a heavy chain variable region of SEQ ID NO: 18 and a light chain variable region of SEQ ID NO: 19,
[0132] (9) an antibody comprising a heavy chain variable region of SEQ ID NO: 20 and a light chain variable region of SEQ ID NO: 21, or
[0133] (10) An antibody comprising the heavy chain variable region of SEQ ID NO: 22 and the light chain variable region of SEQ ID NO: 23.
[0134] [Item 10] A method for detecting the polypeptide of Item 1 or 2, comprising the step of contacting a test sample with the antibody of any one of Items 4 to 9.
[0135] [Item 11] A kit comprising the antibody according to any one of Items 4 to 9.
[0136] [Item 12] The kit according to Item 11, further comprising the polypeptide according to Item 1 or 2.
[0137] [Item 13] The kit according to Item 11 or 12, which is used for determining Alzheimer's disease.
[0138] [Item 14] A reagent for determining Alzheimer's disease, comprising one or more anti-S38AA antibodies capable of measuring the amount of the polypeptide of Item 1 or 2.
[0139] [Item 15] The reagent according to Item 14, wherein the anti-S38AA antibody is the antibody according to any one of Items 4 to 9.
[0140] [Item 16] Use of the antibody according to any one of Items 4 to 9 for the preparation of a reagent for determining Alzheimer's disease.
[0141] [Item 17] A method for determining the possibility that a test animal currently suffers from Alzheimer's disease or that the animal may suffer from Alzheimer's disease in the future, comprising detecting the polypeptide of Item 1 or 2 in a sample collected from the animal.
[0142] [Item 18] The method of Item 17, wherein the polypeptide of Item 1 or 2 is detected using the antibody of any one of Items 4 to 9.
[0143] [Item 19] The method of Item 17 or 18, comprising the following steps (i) to (iii):
[0144] (i) a step of quantifying the polypeptide of [1] in a sample collected from a test animal,
[0145] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from a healthy animal (hereinafter referred to as a control value), and
[0146] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the aforementioned control value, the step of determining that the aforementioned test animal may currently suffer from Alzheimer's disease or the animal may suffer from Alzheimer's disease in the future.
[0147] [Item 20] The method of Item 19, wherein the amount of the polypeptide quantified in (i) is not less than 1.1 times the control value.
[0148] [Item 21] The method of Item 17 or 18, comprising the following steps (i) to (iii):
[0149] (i) a step of quantifying the polypeptide of item 1 or 2 in a sample collected from a test animal, and
[0150] (ii) when the amount of the polypeptide quantified in (i) is higher than the cutoff value, determining that the test animal may currently suffer from Alzheimer's disease or the animal may suffer from Alzheimer's disease in the future.
[0151] [Item 22] The method of Item 21, wherein the aforementioned cutoff value is 45-75 units.
[0152] [Item 23] The method of Item 21, wherein the aforementioned cutoff value is 45 - 75 ng / mL.
[0153] [Item 24] The method of any one of Items 17-23, wherein the aforementioned test animal is a human.
[0154] [Item 25] The method of any one of Items 17-24, wherein the aforementioned sample is blood, cerebrospinal fluid, saliva, tears or urine.
[0155] [Item 26] The method of any one of Items 17-25, further comprising detecting one or more other Alzheimer's disease diagnostic markers.
[0156] [Item 27] A method for determining the progression of Alzheimer's disease, comprising detecting the polypeptide of Item 1 or 2 in a sample collected from a test animal.
[0157] [Item 28] The method of Item 27, wherein the polypeptide of Item 1 or 2 is detected using the antibody of any one of Items 4 to 9.
[0158] [Item 29] The method of Item 27 or 28, comprising the following steps (i) to (iii):
[0159] (i) a step of quantifying the polypeptide of item 1 or 2 in a sample collected from a test animal,
[0160] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from a healthy animal (hereinafter referred to as a control value), and
[0161] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the aforementioned control value, the step of determining that the aforementioned test animal may currently suffer from Alzheimer's disease or the animal may suffer from Alzheimer's disease in the future.
[0162] [Item 30] The method of Item 29, wherein the amount of the polypeptide quantified in (i) is not less than 1.1 times the control value.
[0163] [Item 31] The method of Item 27 or 28, comprising the following steps (i) to (ii):
[0164] (i) a step of quantifying the polypeptide of item 1 or 2 in a sample collected from a test animal, and
[0165] (ii) when the amount of the polypeptide quantified in (i) is higher than the cutoff value, determining that the test animal may currently suffer from Alzheimer's disease or the animal may suffer from Alzheimer's disease in the future.
[0166] [Item 32] The method of Item 31, wherein the aforementioned cutoff value is 45-75 units.
[0167] [Item 33] The method of Item 31, wherein the aforementioned cutoff value is 45 - 75 ng / mL.
[0168] [Item 34] The method of any one of Items 27-34, wherein the aforementioned test animal is a human.
[0169] [Item 35] The method of any one of Items 27-34, wherein the aforementioned sample is blood, cerebrospinal fluid, saliva, tears or urine.
[0170] [Item 36] The method of any one of Items 27-35, further comprising detecting one or more other Alzheimer's disease diagnostic markers.
[0171] [Item 37] A method for treating or preventing Alzheimer's disease, comprising: detecting the polypeptide of Item 1 or 2 in a sample collected from a test animal, and administering a therapeutic drug for Alzheimer's disease to the test animal.
[0172] [Item 38] The method of Item 37, wherein the polypeptide of Item 1 or 2 is detected using the antibody of any one of Items 4 to 9.
[0173] [Item 39] The method of Item 37 or 38, comprising the following steps (i) to (iv):
[0174] (i) a step of quantifying the polypeptide of item 1 or 2 in a sample collected from a test animal,
[0175] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from a healthy animal (hereinafter referred to as a control value),
[0176] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the aforementioned control value, a step of determining that the aforementioned test animal currently suffers from or is likely to suffer from Alzheimer's disease or that the animal is likely to suffer from Alzheimer's disease in the future, and
[0177] (iv) a step of administering a therapeutic or preventive drug for Alzheimer's disease to the test animal determined to currently suffer from or likely suffer from Alzheimer's disease or likely suffer from Alzheimer's disease in the future based on the result of (iii).
[0178] [Item 40] The method of Item 39, wherein the amount of the polypeptide quantified in (i) is not less than 1.1 times the control value.
[0179] [Item 41] The method of Item 37 or 38, comprising the following steps (i) to (ii):
[0180] (i) a step of quantifying the polypeptide of item 1 or 2 in a sample collected from a test animal, and
[0181] (ii) when the amount of the polypeptide quantified in (i) is higher than the cutoff value, determining that the test animal may currently suffer from Alzheimer's disease or the animal may suffer from Alzheimer's disease in the future.
[0182] [Item 42] The method of Item 41, wherein the aforementioned cut-off value is 45-75 units.
[0183] [Item 43] The method of Item 41, wherein the aforementioned cutoff value is 45 - 75 ng / mL.
[0184] [Item 44] The method of any one of Items 37-43, wherein the aforementioned test animal is a human.
[0185] [Item 45] The method of any one of Items 37-44, wherein the aforementioned sample is blood, cerebrospinal fluid, saliva, tears or urine.
[0186] [Item 46] The method of any one of Items 37-45, further comprising detecting one or more other Alzheimer's disease diagnostic markers.
[0187] [Item 47] The method of any one of Items 37-46, wherein the therapeutic drug for Alzheimer's disease is at least one selected from cholinesterase inhibitors, NMDA receptor antagonists, amyloid β removers and production inhibitors, and tau protein removers and production inhibitors.
[0188] [Item 48] The method of Item 47, wherein the aforementioned cholinesterase inhibitor is at least one selected from donepezil, galantamine, rivastigmine, huperzine A and tacrine.
[0189] [Item 49] The method of Item 47, wherein the aforementioned NMDA receptor antagonist is memantine.
[0190] [Item 50] The method of Item 47, wherein the aforementioned amyloid β remover and production inhibitor is at least one selected from an amyloid β vaccine, an amyloid β removal antibody, an amyloid β production enzyme inhibitor, an amyloid β coagulation inhibitor and an amyloid β decomposition promoter.
[0191] [Item 51] The method of Item 47, wherein the aforementioned amyloid β remover and production inhibitor is at least one selected from the following: CNP-520, E-2609, aducanumab, sorazumab, gantenerumab, crenezumab, amilomotide, ASD-005, HSH-971, ELND-005, ALZT-OP1, nilvadipine, ACI-24, UB-311, AFFITOPE AD-02, LY-3002813, BAN-2401, Neurostem-AD, CT-1812, ID-1201, NIC5-15, BI-425809, Posiphen, PQ-912, Bryostatin-1, Apabetalone, PBT-2, RIV-1061-IR, MEDI-1814, PF-05236812, SAR-228810, Lu-AF20513, PRI-002, IRX-4204, GC-021109, AAD-2004, CTS-21166, LY-3323795, benfotiamine, bisnorcymserine, MDR-1339, KHK-6640, and NPT-088.
[0192] [Item 52] The method of Item 47, wherein the aforementioned tau protein remover and production inhibitor is at least one selected from a tau protein vaccine, a tau protein removal antibody, a tau protein modification inhibitor, a tau protein coagulation inhibitor and a tau protein hydrolysis promoter.
[0193] [Item 53] The method of Item 47, wherein the aforementioned tau protein remover and production inhibitor is at least one selected from TRx-237, TPI-287, ABBV-8E12, RG-6100, AADvac1, RO7105705, PTI-80, JNJ-63733657, UCB-0107, BIIB-076, MC-1, ACI-35 and AZP-2006.
[0194] [Item 54] A method for drug treatment for treating or preventing Alzheimer's disease, comprising: quantifying the polypeptide of Item 1 or 2 in a sample collected from a test animal, selecting a therapeutic or preventive drug for Alzheimer's disease, and administering the therapeutic drug for Alzheimer's disease to the test animal.
[0195] [Item 55] The method of Item 54, wherein the polypeptide of Item 1 or 2 above is quantified using the antibody of any one of Items 4 to 9.
[0196] [Item 56] The method of Item 54 or 55, comprising the following steps (i) to (v):
[0197] (i) a step of quantifying the polypeptide of [1] in a sample collected from a test animal currently suffering from or likely to suffer from Alzheimer's disease,
[0198] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from the test animal in the past (hereinafter referred to as a control value),
[0199] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the control value, determining that the Alzheimer's disease in the aforementioned test animal is progressing, and when the amount is lower than the control value, determining that the Alzheimer's disease in the aforementioned test animal is improving,
[0200] (iv) a step of selecting a therapeutic or preventive drug for Alzheimer's disease based on the result of (iii), and
[0201] (v) a step of administering the therapeutic drug for Alzheimer's disease selected in (iv) to the test animal.
[0202] [Item 57] The method of Item 56, wherein when the amount of the polypeptide quantified in (i) is not less than 1.1 times the control value, it is determined that Alzheimer's disease in the test animal is progressing.
[0203] [Item 58] The method of Item 56, wherein when the amount of the polypeptide quantified in (i) is not greater than 0.9 times the control value, it is determined that Alzheimer's disease in the test animal is improving.
[0204] [Item 59] The method of any one of Items 54-58, wherein the aforementioned test animal is a human.
[0205] [Item 60] The method of any one of Items 54-59, wherein the aforementioned sample is blood, cerebrospinal fluid, saliva, tears or urine.
[0206] [Item 61] The method of any one of
[54] to
[60] , further comprising detecting one or more other diagnostic markers for Alzheimer's disease.
[0207] [Item 62] The method of any one of Items 54-61, wherein the therapeutic drug for Alzheimer's disease is selected from cholinesterase inhibitors, NMDA receptor antagonists, amyloid β removers and production inhibitors, and tau protein removers and production inhibitors.
[0208] [Item 63] The method of Item 62, wherein the aforementioned cholinesterase inhibitor is at least one selected from donepezil, galantamine, rivastigmine, huperzine A and tacrine.
[0209] [Item 64] The method of Item 62, wherein the aforementioned NMDA receptor antagonist is memantine.
[0210] [Item 65] The method of Item 62, wherein the aforementioned amyloid β remover and production inhibitor is at least one selected from an amyloid β vaccine, an amyloid β removal antibody, an amyloid β production enzyme inhibitor, an amyloid β coagulation inhibitor and an amyloid β decomposition promoter.
[0211] [Item 66] The method of Item 62, wherein the aforementioned amyloid β remover and production inhibitor is at least one selected from the following: CNP-520, E-2609, aducanumab, sorazumab, gantenerumab, crenezumab, amilomotide, ASD-005, HSH-971, ELND-005, ALZT-OP1, nilvadipine, ACI-24, UB-311, AFFITOPE AD-02, LY-3002813, BAN-2401, Neurostem-AD, CT-1812, ID-1201, NIC5-15, BI-425809, Posiphen, PQ-912, Bryostatin-1, Apabetalone, PBT-2, RIV-1061-IR, MEDI-1814, PF-05236812, SAR-228810, Lu-AF20513, PRI-002, IRX-4204, GC-021109, AAD-2004, CTS-21166, LY-3323795, benfotiamine, bisnorcymserine, MDR-1339, KHK-6640, and NPT-088.
[0212] [Item 67] The method of Item 62, wherein the aforementioned tau protein remover and production inhibitor is at least one selected from a tau protein vaccine, a tau protein removal antibody, a tau protein modification inhibitor, a tau protein coagulation inhibitor and a tau protein hydrolysis promoter.
[0213] [Item 68] The method of Item 62, wherein the aforementioned tau protein remover and production inhibitor is at least one selected from TRx-237, TPI-287, ABBV-8E12, RG-6100, AADvac1, RO7105705, PTI-80, JNJ-63733657, UCB-0107, BIIB-076, MC-1, ACI-35 and AZP-2006.
[0214] [Item 69] A therapeutic agent for Alzheimer's disease in a patient having progression of Alzheimer's disease determined by quantifying the polypeptide of Item 1 or 2 in a sample collected from a test animal.
[0215] [Item 70] The drug of Item 69, wherein the polypeptide of Item 1 or 2 is quantified using the antibody of any one of Items 4 to 9.
[0216] [Item 71] The medicament of Item 69 or Item 70 for use in a patient whose progression of Alzheimer's disease is determined by the following steps (i)-(iv):
[0217] (i) a step of quantifying the polypeptide of item 1 or 2 in a sample collected from a test animal suffering from or likely to suffer from Alzheimer's disease,
[0218] (ii) a step of comparing the amount of the aforementioned polypeptide quantified in (i) with the amount of the aforementioned polypeptide in a sample collected from the test animal in the past (hereinafter referred to as a control value),
[0219] (iii) based on the result of (ii), when the amount of the aforementioned polypeptide quantified in (i) is higher than the control value, determining that Alzheimer's disease in the aforementioned test animal is progressing, and when the amount is lower than the control value, determining that Alzheimer's disease in the aforementioned test animal is improving, and
[0220] (iv) determining the step of administering a therapeutic drug for Alzheimer's disease based on the result of (iii).
[0221] [Item 72] The drug of Item 71, wherein when the amount of the polypeptide quantified in (i) is not less than 1.1 times the control value, it is determined that Alzheimer's disease in the test animal is progressing.
[0222] [Item 73] The drug of Item 71, wherein when the amount of the polypeptide quantified in (i) is not greater than 0.9 times the control value, it is determined that Alzheimer's disease in the test animal is improving.
[0223] [Item 74] The drug of Item 69 or Item 70 for use in a patient, wherein the patient is determined to be likely to currently suffer from Alzheimer's disease or to be likely to suffer from Alzheimer's disease in the future by following the steps (i) to (iv):
[0224] (i) a step of quantifying the polypeptide of item 1 or 2 in a sample collected from a test animal suffering from or likely to suffer from Alzheimer's disease, and
[0225] (ii) when the amount of the polypeptide quantified in (i) is higher than the cut-off value, determining that the test animal may currently suffer from Alzheimer's disease or the animal may suffer from Alzheimer's disease in the future, and
[0226] (iii) a step of determining the administration of a therapeutic drug for Alzheimer's disease based on the result of (ii).
[0227] [Item 75] The drug of Item 74, wherein the aforementioned cutoff value is 45-75 units.
[0228] [Item 76] The drug of Item 74, wherein the aforementioned cutoff value is 45 - 75 ng / mL.
[0229] [Item 77] The drug of any one of Items 69-76, wherein the aforementioned test animal is a human.
[0230] [Item 78] The drug of any one of Items 69-77, wherein the aforementioned sample is blood, cerebrospinal fluid, saliva, tears or urine.
[0231] [Item 79] The drug of any one of Items 69-78, which further comprises detecting one or more other Alzheimer's disease diagnostic markers.
[0232] [Item 80] The drug of any one of Items 69 to 79, wherein the therapeutic drug for Alzheimer's disease is selected from the cholinesterase inhibitors, NMDA receptor antagonists, amyloid β removers and production inhibitors, and tau protein removers and production inhibitors described for Alzheimer's disease.
[0233] [Item 81] The drug of Item 80, wherein the aforementioned cholinesterase inhibitor is at least one selected from donepezil, galantamine, rivastigmine, huperzine A and tacrine.
[0234] [Item 82] The drug of Item 80, wherein the aforementioned NMDA receptor antagonist is memantine.
[0235] [Item 83] The drug of Item 80, wherein the aforementioned amyloid β remover and production inhibitor is at least one selected from an amyloid β vaccine, an amyloid β removal antibody, an amyloid β production enzyme inhibitor, an amyloid β coagulation inhibitor and an amyloid β decomposition promoter.
[0236] [Item 84] The drug of Item 80, wherein the aforementioned amyloid β remover and production inhibitor is at least one selected from the following: CNP-520, E-2609, aducanumab, sorazumab, gantenerumab, crenezumab, amilomotide, ASD-005, HSH-971, ELND-005, ALZT-OP1, nilvadipine, ACI-24, UB-311, AFFITOPE AD-02, LY-3002813, BAN-2401, Neurostem-AD, CT-1812, ID-1201, NIC5-15, BI-425809, Posiphen, PQ-912, Bryostatin-1, Apabetalone, PBT-2, RIV-1061-IR, MEDI-1814, PF-05236812, SAR-228810, Lu-AF20513, PRI-002, IRX-4204, GC-021109, AAD-2004, CTS-21166, LY-3323795, benfotiamine, bisnorcymserine, MDR-1339, KHK-6640, and NPT-088.
[0237] [Item 85] The drug of Item 80, wherein the aforementioned tau protein remover and production inhibitor is at least one selected from a tau protein vaccine, a tau protein removal antibody, a tau protein modification inhibitor, a tau protein coagulation inhibitor and a tau protein hydrolysis promoter.
[0238] [Item 86] The drug of Item 80, wherein the aforementioned tau protein remover and production inhibitor is at least one selected from TRx-237, TPI-287, ABBV-8E12, RG-6100, AADvac1, RO7105705, PTI-80, JNJ-63733657, UCB-0107, BIIB-076, MC-1, ACI-35 and AZP-2006.
[0239] [Item 87] A therapeutic or preventive drug for Alzheimer's disease, comprising the following as an active ingredient: a drug that reduces the amount of the polypeptide of Item 1 or Item 2 in the body of an Alzheimer's disease patient or a person who may suffer from Alzheimer's disease, or a drug that inhibits the production of the polypeptide in the body of an Alzheimer's disease patient or a person who may suffer from Alzheimer's disease.
[0240] [Item 88] The drug of Item 87, wherein the polypeptide of Item 1 or 2 is detected using the antibody of any one of Items 4 to 9.
[0241] [Item 89] A method for screening candidate substances for therapeutic or preventive drugs for Alzheimer's disease, comprising using the following as an indicator: a reduction in the amount of the polypeptide of Item 1 or 2 in the body of an Alzheimer's disease patient or a person who may suffer from Alzheimer's disease, or an inhibition of the production of the polypeptide in the body of an Alzheimer's disease patient or a person who may suffer from Alzheimer's disease.
[0242] [Item 90] The method of Item 89, wherein the reduction in the amount of the polypeptide of Item 1 or 2 is detected using the antibody of any one of Items 4 to 9.
[0243] [Advantageous Effects of the Invention]
[0244] According to the present invention, a reagent for determining Alzheimer's disease, a method for determining Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening candidate compounds for therapeutic drugs for Alzheimer's disease, a novel anti-S38AA antibody, etc. can be provided. [Brief Description of the Figures]
[0246] Figure 1 The amino acid sequence of S38AA is shown. The sequence of the peptide detected by the LC-MS / MS method in the N-terminus identifying the long fragment of S38AA is shown in bold letters.
[0247] Figure 2 Shown in the identification of the N-terminus of the S38AA long fragment detected by LC-MS / MS method 399 EEVPEDLAEEAPGGR 413 MS / MS peak spectrum of a peptide. The vertical axis shows the peak intensity of each ion, and the horizontal axis shows m / z.
[0248] Figure 3 The amino acid sequence of S38AA is shown. The sequence of the peptide detected by the LC-MS / MS method in the N-terminus identifying the short fragment of S38AA is shown in bold letters.
[0249] Figure 4 Shown in the identification of the N-terminus of the S38AA short fragment detected by LC-MS / MS method 617 GLAVGGGEKAK 627 MS / MS peak spectrum of a peptide. The vertical axis shows the peak intensity of each ion, and the horizontal axis shows m / z.
[0250] Figure 5 The amino acid sequence of S38AA is shown. The sequence of the peptide detected by the LC-MS / MS method in the C-terminus of the long fragment identifying S38AA is shown in bold letters.
[0251] Figure 6Shown in the identification of the C-terminus of the S38AA long fragment detected by LC-MS / MS method 1040 DLKLQAGSDL 1049 MS / MS peak spectrum of a peptide. The vertical axis shows the peak intensity of each ion, and the horizontal axis shows m / z.
[0252] Figure 7 Shows quantification (calibration curve) when the expression levels of recombinant proteins of the S38AA long fragment and the S38AA short fragment in E. coli were measured by the long ELISA and total ELISA measurement systems, respectively. The vertical axis of each graph shows the absorbance at 450 nm, and the horizontal axis shows the concentration of each protein.
[0253] Figure 8 The quantitative values in each sample when the S38AA long fragment and the S38AA short fragment in human plasma are quantified by subtraction are shown. The vertical axis shows the quantitative values of the S38AA long fragment and the S38AA short fragment, and the horizontal axis shows each sample. Numbers starting with D indicate healthy individuals, and numbers starting with AG indicate patients with moderate and severe AD.
[0254] Fig. 9 The quantitative values in each group when the S38AA long fragment (left figure) and the S38AA short fragment (right figure) in human plasma are quantified by subtraction are shown. The vertical axis shows the quantitative values of the S38AA long fragment and the S38AA short fragment, and the horizontal axis shows each group. Individual samples are shown in each figure. The bars show (mean ± standard deviation of each group).
[0255] Fig.10 The quantitative values in each group when the S38AA long fragment and the S38AA short fragment in human plasma were quantified by the immunoprecipitation removal method are shown. The vertical axis shows the quantitative values of the S38AA long fragment and the S38AA short fragment, and the horizontal axis shows each group.
[0256] Fig.11 The quantitative values in each sample when the S38AA long fragment and the S38AA short fragment in human plasma are quantified by subtraction are shown. The vertical axis shows the quantitative values of the S38AA long fragment and the S38AA short fragment, and the horizontal axis shows each sample. Numbers starting with TSUM indicate healthy individuals, and numbers starting with ASUM indicate patients with mild AD.
[0257] Fig.12The quantitative values in each group when quantifying the S38AA long fragment and the S38AA short fragment in human plasma by subtraction (left figure), the S38AA short fragment (middle figure), and the S38AA long fragment (right figure) are shown. The vertical axis shows the quantitative values of the S38AA long fragment and the S38AA short fragment, and the horizontal axis shows each group. Individual samples are shown in each figure. The bars show (mean ± standard deviation of each group).
[0258] Fig.13 The recognition sites of antibodies (Antibody A, Antibody B, and Antibody C) for long fragments are shown.
[0259] Fig.14 The quantitative values in each sample when the S38AA fragment in human plasma is quantified by combining various anti-S38AA fragment antibodies are shown. The combination of antibodies includes 3 modes of antibody A and antibody B, antibody A and antibody C, and antibody B and antibody C, and ELISA is performed using the combination. The vertical axis shows the quantitative value of the total amount of the S38AA fragment, and the horizontal axis shows each sample. Numbers starting with TSUM indicate healthy individuals, and numbers starting with ASUM indicate AD patients.
[0260] Fig.15 The quantitative values in each sample when the S38AA fragment in human plasma is quantified by combining various anti-S38AA fragment antibodies are shown. The combination of antibodies includes 3 modes of antibody for long fragment and antibody A, antibody for long fragment and antibody B, and antibody for long fragment and antibody C, and ELISA is performed using the combination. The vertical axis shows the quantitative value of the S38AA long fragment, and the horizontal axis shows each sample. Numbers starting with TSUM indicate healthy individuals, and numbers starting with ASUM indicate AD patients.
[0261] Fig.16 Display based on Fig.14 and 15 The results of quantification of the S38AA short fragment in human plasma by subtraction show the quantitative values in each sample. The vertical axis shows the quantitative value of the S38AA short fragment, and the horizontal axis shows each sample. Numbers starting with TSUM indicate healthy individuals, and numbers starting with ASUM indicate AD patients.
[0262] [Description of Embodiment]
[0263] In the present specification, "Alzheimer's disease" includes both the aforementioned "familial Alzheimer's disease" and "sporadic Alzheimer's disease".
[0264] In the present invention, "suffering from Alzheimer's disease", that is, "Alzheimer's disease patient" refers to a condition that can be diagnosed as Alzheimer's disease by clinical diagnosis based on impairment of memory or cognitive function or by diagnostic imaging based on brain atrophy, etc.
[0265] In the present specification, "having Alzheimer's disease" means a condition diagnosed as having Alzheimer's disease based on the clinical diagnostic criteria for Alzheimer's disease (for example, the diagnostic criteria of the National Institute of Neurological Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA), or the Revised Diagnostic Criteria for Alzheimer's Disease of the National Institute on Aging and Alzheimer's Association (NIA-AA) (hereinafter referred to as "Revised Diagnostic Criteria for Alzheimer's Disease (2011)"), etc.).
[0266] Among all the diagnostic criteria, the presence of cognitive dysfunction focused on memory impairment, slow onset and progressive course, impairment of social life and daily living activities related to cognitive impairment, and differentiation / rejection of non-AD dementia are indicators of diagnosis.
[0267] Depending on the severity of the symptoms, the onset of Alzheimer's disease is divided into three stages (mild, moderate (or medium), higher (or severe) or stage I (or amnesia stage), stage II (or confusion period), stage III (or lying period). The severity can be assessed using the Mini-Mental State Examination (MMSE) (which measures the degree of cognitive dysfunction), the Functional Assessment Staging of Dementia (FAST) (which determines the severity mainly based on daily living activities), the Clinical Dementia Rating (CDR) (which determines the severity clinically), the Alzheimer's Disease Cognitive Assessment Scale (ADAS-cog) used in clinical tests, and the Severe Impairment Inventory (SIB), etc.
[0268] As a method for evaluating the degree of cognitive dysfunction in Alzheimer's disease, for example, the score of the Mini Mental State Examination (MMSE) can be used as one of the criteria. In a scale of 0 to 30, as a guide, no more than 9 points are judged as severe Alzheimer's disease, 10 to 19 points are judged as moderate Alzheimer's disease, 20 to 23 points are judged as mild Alzheimer's disease, and 24 points or more are judged as mild cognitive impairment or normal.
[0269] In the present specification, "a person at risk of Alzheimer's disease" (pre-Alzheimer's disease), that is, "a person (person) who may suffer from Alzheimer's disease", "a person (person) in a high-risk group for Alzheimer's disease" includes a person in a state where the accumulation of Aβ and tau protein in brain tissue has begun and Alzheimer's disease is highly likely to develop in the near future, that is, a state where Aβ and tau protein accumulate in brain tissue (also called preclinical AD), even if the onset of Alzheimer's disease cannot be diagnosed according to the aforementioned diagnosis. Here, the accumulation of Aβ or tau protein in brain tissue can be confirmed using amyloid PET or tau PET, Aβ or phosphorylated tau in cerebrospinal fluid, etc. as a biomarker.
[0270] In the present specification, as defined in the preclinical AD research criteria in the aforementioned Revised Diagnostic Criteria for Alzheimer's Disease (2011), "preclinical AD" is a state in which biomarkers suggestive of Alzheimer's pathology are positive, but cognitive function is normal or only mild cognitive dysfunction that does not meet the diagnostic criteria for mild cognitive impairment (MCI) is found.
[0271] A person who is not diagnosed with Alzheimer's disease but is diagnosed with mild cognitive impairment is included in the "person (person) who may have Alzheimer's disease" because the symptom is a sign of Alzheimer's disease and may cause Alzheimer's disease in the future.
[0272] In this specification, "mild cognitive impairment (or mild cognitive dysfunction)" (MCI) is an intermediate state between normal and dementia, in which cognitive function is worse than normal but daily life is maintained and dementia is not diagnosed, that is, a prodromal state of dementia.
[0273] Diagnosis of mild cognitive impairment can be made based on, for example, the diagnostic criteria proposed at the 2003 MCI Key Symposium (Winblad B et al., (2004) J. Intern. Med. 256: 240-246) or the diagnostic criteria for mild cognitive impairment described in the aforementioned revised diagnostic criteria for Alzheimer's disease by the NIA-AA (2011).
[0274] When the assessment score of the severity of dementia is an indicator, as a guide, a CDR (Clinical Dementia Rating) score of 0.5 (suspected dementia) or a FAST (Functional Assessment Staging) stage of 3 (suspected dementia) corresponds to mild cognitive impairment. When the aforementioned MMSE score is an indicator, as a guide, a score of not less than 24 without diagnosis of Alzheimer's disease corresponds to mild cognitive impairment. A score of 24-28 indicates a high possibility of mild cognitive impairment.
[0275] 1. Polypeptides of the present invention
[0276] The present inventors have first discovered that the amount of the S38AA long fragment produced by cleavage in the extramembrane portion of S38AA increases in the blood of AD patients, and further, in the blood of AD patients, an enzyme that specifically cleaves the C-terminal side of the long fragment exists or the activity of the enzyme is high, and the amount of the S38AA short fragment significantly increases, and the amount of the S38AA short fragment in the blood is higher than that in healthy individuals, regardless of whether the severity of Alzheimer's disease (progression of cognitive dysfunction) is mild, moderate or severe, and it is higher in moderate and severe than in mild. Therefore, they have discovered that the amount of the S38AA short fragment is very reliable as a highly accurate indicator for determining the onset of Alzheimer's disease and people at risk of the disease.
[0277] Therefore, the present invention first provides a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:1 as a S38AA short fragment (corresponding to the 617th to 1049th amino acid sequence in the amino acid sequence (1-1119) of S38AA shown in SEQ ID NO:3), and a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:2 as a S38AA long fragment (corresponding to the 399th to 1049th amino acid sequence in the amino acid sequence (1-1119) of S38AA shown in SEQ ID NO:3).
[0278] As long as it is recognized by an antibody that specifically binds to a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1 below, 1 to several amino acids in the amino acid sequence of the short S38AA fragment may be substituted, deleted, added or inserted. Similarly, as long as it is recognized by an antibody that specifically binds to a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 2 below, 1 to several amino acids in the amino acid sequence of the long S38AA fragment may be substituted, deleted, added or inserted. As used herein, several is not particularly limited and may be, for example, 2-10, 2-8, 2-6, 2-4, 2-3 or 2.
[0279] The S38AA short fragment can be modified at its N-terminus, C-terminus or side chain by methods well known to those skilled in the art, such as N-terminal acetyl modification, C-terminal amide modification, addition of protein tags (His tag, etc.) to the N-terminus and / or C-terminus, addition of sugar chains to the side chains, etc.
[0280] The polypeptide of the present invention can be produced according to known peptide synthesis methods, such as solid phase synthesis methods, liquid phase synthesis methods, etc. The obtained polypeptide can be purified and isolated by known purification methods, such as solvent extraction, distillation, column chromatography, liquid chromatography, recrystallization, combinations of these, etc.
[0281] The polypeptide of the present invention can also be produced by culturing a transformant containing a nucleic acid encoding the polypeptide and isolating and purifying the polypeptide from the resulting culture. The nucleic acid encoding the polypeptide of the present invention can be DNA, RNA or a DNA / RNA chimera, but is preferably DNA. The nucleic acid can be double-stranded or single-stranded. In the case of double-stranded, it can be a double-stranded DNA, double-stranded RNA or a hybrid of DNA: RNA. In the case of a single strand, it can be a sense strand (i.e., a coding strand) or an antisense strand (i.e., a non-coding strand).
[0282] In this specification, "SEQ ID NO" and "SEQ ID NO:" are synonyms. For example, "SEQ ID NO 1" and "SEQ ID NO:1" are synonyms.
[0283] The DNA encoding the polypeptide of the present invention includes synthetic DNA and the like, and can be obtained by a method known per se, such as the reverse transcription-PCR method, the ODA-LA PCR method, the gap duplex method, the Kunkel method and the like, or the colony or plaque hybridization method or the PCR method.
[0284] 2. Anti-S38AA antibody
[0285] The "anti-S38AA antibody" used in this specification is not particularly limited as long as it is an antibody that specifically recognizes S38AA or an antibody that specifically recognizes the S38AA long fragment and / or the S38AA short fragment. For example, an antibody that recognizes the N-terminal region of the S38AA long fragment, an antibody that recognizes the C-terminal region of the S38AA long fragment, an antibody that recognizes the C-terminal region common to the S38AA long fragment and the S38AA short fragment, etc. can be mentioned.
[0286] The anti-S38AA antibody may also be a commercially available anti-S38AA antibody, a polyclonal or monoclonal antibody or a fragment thereof (eg, Fab, F(ab')2, ScFv, minibody, etc.) produced by a known method.
[0287] As the anti-S38AA antibody to be used in the present invention, monoclonal antibodies and polyclonal antibodies derived from mammals are preferred.
[0288] Examples of monoclonal antibodies and polyclonal antibodies derived from mammals include those produced in the blood of animals, those produced by hybridomas, and those produced by hosts transformed with expression vectors containing antibody genes by genetic engineering means, those produced in large quantities in CHO cells having genes for optimal antibodies screened by phage display from a huge clone library consisting of 1,000,000,000,000 molecules, or human antibodies directly produced using human antibody-producing transgenic mice, and the like.
[0289] Monoclonal antibodies and polyclonal antibodies can be produced by methods known to those of ordinary skill in the art.
[0290] (1) Production of monoclonal antibodies
[0291] The polypeptide of the present invention is administered alone or together with a carrier or diluent to a site where antibodies can be produced by administration to a mammal. In order to increase antibody productivity by administration, complete Freund's adjuvant or incomplete Freund's adjuvant may also be administered. Administration is usually performed once every 2-6 weeks, and about 2-10 times in total. Examples of mammals to be used include monkeys, rabbits, dogs, guinea pigs, mice, rats, sheep and goats, with mice and rats being preferred.
[0292] In order to produce monoclonal antibody cells from mammals (e.g., mice) immunized with antigens, individuals showing antibody titers are selected, spleens or lymph nodes are collected 2-5 days after the final immunization, and the antibody-producing cells contained therein are fused with myeloma cells, thereby preparing hybridomas producing monoclonal antibodies. Antibody titers in antiserum can be measured, for example, as follows: react the following labeled S38AA with the antiserum, and measure the activity of the marker bound to the antibody. Fusion operations can be performed by known methods (e.g., the method of Köhler and Milstein [Nature, 256, 495 (1975)]). As fusion stimulants, for example, polyethylene glycol (PEG), Sendai virus, etc. can be mentioned, and PEG is preferably used. In addition, in order to enhance fusion efficiency, adjuvants such as dimethyl sulfoxide can also be appropriately used.
[0293] As myeloma cells, for example, NS-1, P3U1, SP2 / 0, etc. can be mentioned, and P3U1 is preferably used. The preferred ratio of the number of antibody-producing cells (splenocytes) and myeloma cells to be used is about 1:1 - 20:1, PEG (preferably PEG 1000-PEG 6000) is added at a concentration of about 10-80%, and cell fusion can be efficiently performed by incubating at about 20-40° C., preferably about 30-37° C. for about 1 – 10 min.
[0294] In order to screen hybridomas that produce monoclonal antibodies, various methods can be used. Examples thereof include: a method comprising adding the hybridoma culture supernatant to a solid phase (e.g., a microplate) adsorbed directly or together with a carrier with an antigen (such as a protein), adding an anti-immunoglobulin antibody labeled with a radioactive substance, an enzyme, etc. (when the cells used for cell fusion are from mice, an anti-mouse immunoglobulin antibody is used) or protein A, and detecting the monoclonal antibody bound to the solid phase; a method comprising adding the hybridoma culture supernatant to a solid phase adsorbed with an anti-immunoglobulin antibody or protein A, adding a protein labeled with a radioactive substance, an enzyme, etc., and detecting the monoclonal antibody bound to the solid phase, etc.
[0295] The monoclonal antibody can be selected by a method known per se or a method similar thereto, and can usually be selected using a culture medium of an animal cell added with HAT (hypoxanthine, aminopterin, thymidine), etc. As a culture medium for selection and growth, any culture medium can be used as long as the hybridoma can grow. For example, RPMI 1640 culture medium containing 1-20%, preferably 10-20% fetal bovine serum, GIT culture medium (WakoPure Chemical Industries, Ltd.) containing 1-10% fetal bovine serum, serum-free culture medium (SFM-101, NissuiPharmaceutical Co., Ltd.) for hybridoma culture, etc. can be used. The culture temperature is usually 20-40°C, preferably about 37°C. The culture time is usually 5 days - 3 weeks, preferably 1 week - 2 weeks. Cultivation can usually be carried out in 5% carbon dioxide gas. The antibody titer of the hybridoma culture supernatant can be measured in the same manner as the measurement of the antibody titer of the above-mentioned antiserum.
[0296] The monoclonal antibody can be separated and purified according to the separation and purification method of immunoglobulin in the same manner as in the separation and purification of conventional polyclonal antibodies [e.g., salting-out method, alcohol precipitation method, isoelectric precipitation method, electrophoresis, adsorption and desorption method by ion exchanger (e.g., DEAE), ultracentrifugation method, gel filtration method, including collection of only antibodies by active adsorbent (such as antigen-bound solid phase, protein A, protein G, etc.) and specific purification method of dissociating bonds to produce antibodies].
[0297] (2) Production of polyclonal antibodies
[0298] Polyclonal antibodies against the polypeptide of the present invention can be produced by a method known per se or a method analogous thereto. For example, polyclonal antibodies can be produced by producing a complex of an immunizing antigen (antigen, such as a protein, etc.) and a carrier protein, immunizing a mammal or chicken in the same manner as the above-mentioned monoclonal antibody production method, collecting a substance containing antibodies against S38AA from the immunized animal, and isolating and purifying the antibody.
[0299] As for the complex of the immunizing antigen and the carrier protein to be used for immunizing mammals or chickens, the kind of the carrier protein and the mixing ratio of the carrier and the hapten may be any and any ratio as long as antibodies can be effectively produced against the hapten cross-linked with the carrier for immunization. For example, a complex comprising bovine serum albumin, bovine thyroglobulin, keyhole limpet protein and the like in a weight ratio of about 0.1-20, preferably about 1-5, may be used. A method of coupling hemocyanin and the like with a hapten (1).
[0300] Although various condensing agents can be used for coupling the hapten and the carrier, activated ester reagents containing glutaraldehyde, carbodiimide, maleimide activated ester, thiol group and dithiopyridyl group and the like can be used.
[0301] The condensed product is administered alone or together with a carrier and a diluent to the antibody-producing site of a mammal or chicken. In order to increase antibody productivity by administration, complete Freund's adjuvant or incomplete Freund's adjuvant may also be administered. Administration is usually performed once every 2 to 6 weeks, and about 3 to 10 times in total.
[0302] The polyclonal antibody can be collected from the blood, ascites, breast milk, etc., preferably from the blood, of the mammal immunized by the above method, and in the case of chicken, it can be collected from the blood and egg yolk.
[0303] The titer of the polyclonal antibody in the antiserum can be measured in the same manner as in the measurement of the antibody titer of the antiserum described above. The polyclonal antibody can be separated and purified in the same manner as in the separation and purification of the monoclonal antibody described above according to the separation and purification method of immunoglobulin.
[0304] As the polyclonal antibody in the present invention, for example, a rabbit-derived anti-S38AA polyclonal antibody (hereinafter also referred to as "MBL" or "antibody for long fragment") can be mentioned. The antibody for long fragment is characterized in that it specifically recognizes the S38AA long fragment and does not recognize the S38AA short fragment. By using the antibody for long fragment together with antibody A, B or C, the antibody for long fragment can be used for long ELISA described later.
[0305] (3) Antibodies that specifically recognize the short fragment of S38AA
[0306] As one embodiment of the present invention, an antibody that specifically recognizes the S38AA short fragment shown in SEQ ID NO: 1 can be mentioned. As an antibody that specifically recognizes the S38AA short fragment, for example, an antibody that recognizes the C-terminal sequence or N-terminal sequence of the S38AA short fragment can be mentioned. The antibody that specifically recognizes the S38AA short fragment can be prepared by a method well known to those skilled in the art. For example, it can be obtained as follows: using a peptide consisting of several amino acids from the N-terminus of the S38AA short fragment (glycine at position 617 in the amino acid sequence shown in SEQ ID NO: 3) as an immune antigen, and selecting an antibody that is negative for the peptide, the peptide being an immune antigen or a S38AA long fragment to which several amino acids are added to its N-terminal side. Specifically, a monoclonal antibody or a polyclonal antibody can be obtained according to the aforementioned method (1) or (2), respectively.
[0307] Examples of antibodies that specifically recognize the short fragment of S38AA include Antibody A, Antibody B, and Antibody C described below.
[0308] Antibody A (hereinafter also referred to as "mouse-derived anti-S38AA monoclonal antibody A") is an antibody that recognizes the C-terminal region of S38AA, and means an antibody obtained by establishing an antibody-producing hybridoma using a portion of a peptide of the C-terminal amino acid sequence of the S38AA fragment as an immunogen, followed by separation and purification. Antibody A is characterized in that it specifically recognizes a short S38AA fragment and a long S38AA fragment. Antibody A can be used for long ELISA together with "antibody for long fragments". By using antibody A together with antibody B or C, antibody A can be used for total ELISA described later.
[0309] Antibody A is preferably an antibody selected from the following:
[0310] (1) an antibody comprising a heavy chain variable region of SEQ ID NO: 4,
[0311] (2) an antibody comprising a heavy chain variable region of SEQ ID NO: 6,
[0312] (3) an antibody comprising a heavy chain variable region of SEQ ID NO: 8, and
[0313] (4) An antibody comprising the heavy chain variable region of SEQ ID NO:10.
[0314] Another preferred embodiment of antibody A is an antibody selected from the group consisting of:
[0315] (1) an antibody comprising a light chain variable region of SEQ ID NO: 5,
[0316] (2) an antibody comprising a light chain variable region of SEQ ID NO: 7,
[0317] (3) an antibody comprising a light chain variable region of SEQ ID NO: 9, and
[0318] (4) An antibody comprising the light chain variable region of SEQ ID NO:11.
[0319] More preferably, antibody A is an antibody selected from the group consisting of:
[0320] (1) an antibody comprising a heavy chain variable region of SEQ ID NO: 4 and a light chain variable region of SEQ ID NO: 5,
[0321] (2) an antibody comprising a heavy chain variable region of SEQ ID NO: 6 and a light chain variable region of SEQ ID NO: 7,
[0322] (3) an antibody comprising a heavy chain variable region of SEQ ID NO: 8 and a light chain variable region of SEQ ID NO: 9, and
[0323] (4) An antibody comprising the heavy chain variable region of SEQ ID NO: 10 and the light chain variable region of SEQ ID NO: 11.
[0324] Antibody B is an antibody that recognizes the C-terminal region of S38AA, and means an antibody obtained by establishing a hybridoma that produces an antibody using a portion of a peptide of the C-terminal amino acid sequence of the S38AA fragment as an immunogen, followed by separation and purification. Antibody B is characterized in that it specifically recognizes a short S38AA fragment and a long S38AA fragment. Antibody B can be used in long ELISA together with "antibodies for long fragments". By using antibody B together with antibody A or C, antibody B can be used in total ELISA.
[0325] Antibody B is preferably an antibody selected from the following:
[0326] (5) an antibody comprising a heavy chain variable region of SEQ ID NO: 12,
[0327] (6) an antibody comprising the heavy chain variable region of SEQ ID NO: 14,
[0328] (7) an antibody comprising a heavy chain variable region of SEQ ID NO: 16, and
[0329] (8) An antibody comprising the heavy chain variable region of SEQ ID NO:18.
[0330] Another preferred embodiment of antibody B is an antibody selected from the group consisting of:
[0331] (5) an antibody comprising a light chain variable region of SEQ ID NO: 13,
[0332] (6) an antibody comprising a light chain variable region of SEQ ID NO: 15,
[0333] (7) an antibody comprising the light chain variable region of SEQ ID NO: 17, and
[0334] (8) An antibody comprising the light chain variable region of SEQ ID NO: 19.
[0335] Antibody B is more preferably an antibody selected from the following:
[0336] (5) an antibody comprising a heavy chain variable region of SEQ ID NO: 12 and a light chain variable region of SEQ ID NO: 13,
[0337] (6) an antibody comprising a heavy chain variable region of SEQ ID NO: 14 and a light chain variable region of SEQ ID NO: 15,
[0338] (7) an antibody comprising a heavy chain variable region of SEQ ID NO: 16 and a light chain variable region of SEQ ID NO: 17, and
[0339] (8) An antibody comprising the heavy chain variable region of SEQ ID NO: 18 and the light chain variable region of SEQ ID NO: 19.
[0340] Antibody C is an antibody that recognizes the C-terminal region of S38AA, and means an antibody obtained by establishing an antibody-producing hybridoma using a recombinant protein of a long fragment of S38AA in Escherichia coli as an immunogen, followed by separation and purification. Antibody C is characterized in that it specifically recognizes a short fragment of S38AA and a long fragment of S38AA. Antibody C can be used in long ELISA together with "antibodies for long fragments". By using antibody C together with antibody A or B, antibody C can be used in total ELISA.
[0341] Antibody C is preferably an antibody selected from the following:
[0342] (9) an antibody comprising a heavy chain variable region of SEQ ID NO: 20, and
[0343] (10) An antibody comprising the heavy chain variable region of SEQ ID NO:22.
[0344] Another preferred embodiment of antibody C is an antibody selected from the following:
[0345] (9) an antibody comprising a light chain variable region of SEQ ID NO: 21, and
[0346] (10) An antibody comprising a light chain variable region of SEQ ID NO: 23.
[0347] Antibody C is more preferably an antibody selected from the following:
[0348] (9) an antibody comprising a heavy chain variable region of SEQ ID NO: 20 and a light chain variable region of SEQ ID NO: 21, and
[0349] (10) An antibody comprising the heavy chain variable region of SEQ ID NO: 22 and the light chain variable region of SEQ ID NO: 23.
[0350] As long as the antibodies A, B and C of the present invention can specifically recognize the S38AA short fragment and the S38AA long fragment, the corresponding antibodies may contain a variable region having an homology of not less than 90%, preferably not less than 95%, more preferably not less than 96%, still more preferably not less than 97%, further preferably 98%, further more preferably not less than 99%, and most preferably not less than 99.5% to the amino acid sequence of the aforementioned variable region contained therein.
[0351] In this specification, "homology" means the proportion (%) of identical amino acids and similar amino acid residues to the total amino acid residues that overlap in the optimal alignment when two amino acid sequences are aligned using a mathematical algorithm known in the technical field (preferably, for optimal alignment, the algorithm can take into account the introduction of gaps into one or both sequences).
[0352] The homology of the amino acid sequences in the present specification can be calculated using the homology calculation algorithm NCBI BLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool) under the following conditions (expectation value = 10; gap; matrix = BLOSUM62; filter = OFF). Examples of other algorithms for determining amino acid sequence homology include the algorithm described in Karlin et al., Proc. Natl. Acad. Sci. USA, 90:5873-5877 (1993) [which algorithm was incorporated into the NBLAST and XBLAST programs (version 2.0) (Altschul et al., Nucleic Acids Res., 25:3389-3402 (1997))], the algorithm described in Needleman et al., J. Mol. Biol., 48:444-453 (1970) [which algorithm was incorporated into the GAP program in the GCG software package], the algorithm described in Myers and Miller, CABIOS, 4:11-17 (1988) [which algorithm was incorporated into the ALIGN program (version 2.0), which is part of the CGC sequence alignment software package], Pearson et al., Proc. Natl. Acad. Sci. USA, 85: 2444-2448 (1988) [this algorithm is incorporated into the FASTA program in the GCG software package] and the like, and they can also be preferably used in the same manner.
[0353] The CDR contained in the antibodies A, B and C of the present invention may contain 1 to several (2, 3, 4, 5, etc.) substituted, deleted, inserted and / or added in the amino acid sequence of one CDR, preferably within 2, more preferably one amino acid, as long as the antibody can specifically recognize the S38AA short fragment and the S38AA long fragment. The number of CDRs in which the amino acids of each of the above antibodies are substituted, deleted, inserted and / or added is not particularly limited, as long as each antibody can specifically recognize the S38AA short fragment and the S38AA long fragment. It is preferably within 2, more preferably 1, per 1 light chain variable region, and preferably within 2, more preferably 1, per 1 heavy chain variable region. Amino acid substitution, deletion, insertion and / or addition may be performed in both the light chain variable region and the heavy chain variable region, or in either one alone.
[0354] For example, "similar amino acids" means amino acids with similar physicochemical properties, and, for example, amino acids classified into the same group can be mentioned, such as aromatic amino acids (Phe, Trp, Tyr), aliphatic amino acids (Ala, Leu, Ile, Val), polar amino acids (Gln, Asn), basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), amino acids with hydroxyl groups (Ser, Thr), amino acids with small side chains (Gly, Ala, Ser, Thr, Met), etc. It is predicted that substitution with such similar amino acids will not cause a change in the phenotype of the protein (i.e., conservative amino acid substitutions). The specific examples of conservative amino acid substitutions are well known in the art and are described in various documents (see, for example, Bowie et al., Science, 247: 1306-1310 (1990)).
[0355] Examples of methods for replacing one or more amino acid residues with other desired amino acids include site-directed mutagenesis (Hashimoto-Gotoh, T, Mizuno, T, Ogasahara, Y, and Nakagawa, M. (1995) Anoligodeoxyribonucleotide-directed dual amber method for site-directed mutagenesis. Gene 152, 271-275, Zoller, MJ, and Smith, M. (1983) Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors. Methods Enzymol. 100, 468-500, Kramer, W, Drutsa, V, Jansen, HW, Kramer, B, Pflugfelder, M, and Fritz, HJ (1984) The gapped duplex DNA approach to oligonucleotide-directed mutation construction. Nucleic Acids Res. 12,9441-9456, Kramer W, and Fritz HJ (1987) Oligonucleotide-directed constructionof mutations via gapped duplex DNA Methods. Enzymol. 154, 350-367, Kunkel, TA (1985) Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci USA. 82,488-492). Using this method, the desired amino acid of the antibody can be replaced by other desired amino acids. By using library technology, such as framework reorganization (Mol Immunol. 2007 Apr; 44 (11): 3049-60) and CDR repair (US2006 / 0122377), it is also possible to replace the amino acid in the framework and CDR with other appropriate amino acids.
[0356] 3. Reagents used to determine Alzheimer's disease
[0357] The determination reagent of the present invention contains one or more anti-S38AA antibodies capable of detecting the amount of the S38AA short fragment, and can determine not only whether a person has Alzheimer's disease and whether it is currently very likely to have the disease, but also a person at risk of Alzheimer's disease, that is, whether the person has a high probability of having the disease in the near future, although the person has not yet had the disease. In other words, the reagent of the present invention can identify Alzheimer's disease regardless of whether the severity is mild, moderate or severe. Therefore, the "determination" of Alzheimer's disease in the present invention is not only used to mean determining whether a person has already had Alzheimer's disease and whether it is currently very likely to have the disease, but also covers judging whether a person has a high probability of having the disease in the near future, although the person has not yet had the disease.
[0358] 4. Kit for determining Alzheimer's disease
[0359] The present invention provides a kit for determining Alzheimer's disease. The kit of the present invention comprises a reagent for measuring the amount of the S38AA short fragment. By measuring the amount of the S38AA short fragment using the kit of the present invention, Alzheimer's disease can be determined.
[0360] The kit of the present invention contains an anti-S38AA antibody, which is a single antibody or a combination of multiple antibodies capable of quantifying a short S38AA fragment, and specifically, an antibody that specifically recognizes a short S38AA fragment or an antibody that recognizes a long S38AA fragment and does not recognize a short S38AA fragment, and a combination of antibodies that recognize both a long S38AA fragment and a short S38AA fragment. As an antibody that recognizes a long S38AA fragment and does not recognize a short S38AA fragment, for example, an antibody that recognizes the N-terminal side region of the aforementioned long S38AA fragment can be mentioned. As an antibody that recognizes both a long S38AA fragment and a short S38AA fragment, an antibody that recognizes a C-terminal side region common to a long S38AA fragment and a short S38AA fragment can be mentioned.
[0361] The antibody used in the kit of the present invention is preferably an antibody for long fragments, antibody A, antibody B and / or antibody C.
[0362] The antibody may be a fluorescently labeled antibody, an enzyme-labeled antibody, a streptavidin-labeled antibody, a biotin-labeled antibody or a radioactively labeled antibody.
[0363] The anti-S38AA antibody is generally included in the kit of the present invention in the form of an aqueous solution or a lyophilized product dissolved in water or a suitable buffer (eg, TE buffer, PBS, etc.) at a suitable concentration.
[0364] In order to measure the S38AA short fragment and / or the S38AA long fragment, one antibody may be used for measurement, and a plurality of, preferably two antibodies may be used for measurement (eg, sandwich ELISA method, etc.).
[0365] According to the measurement method of the short S38AA fragment, the kit of the present invention may further contain other components necessary for performing the method in its composition. For example, in order to measure by Western blotting, the kit of the present invention may further contain blotting buffer, labeling reagent, blotting membrane, etc., assay reagent, standard solution, etc. Examples of "standard solution" herein include purified reference standards of S38AA short fragments and / or S38AA long fragments, for example, an aqueous solution obtained by dissolving the peptide of the present invention at a specific concentration in water or a suitable buffer (e.g., TE buffer, PBS containing fetal bovine serum, etc.).
[0366] For measurement by sandwich ELISA, in addition to the above, the kit of the present invention may further contain a fixed antibody measurement plate, a washing solution, etc. For measurement by agglutination methods (including latex agglutination methods), antibody-coated latex, gelatin, etc. may be contained. For measurement by chemiluminescence methods or chemiluminescence electronic methods, antibody-conjugated magnetic particles and a suitable buffer may be contained. For detection of S38AA by using LC / MS, LC-MS / MS or immunochromatography methods, antibody-coated columns or microcolumns and microchips may be contained as part of the detection instrument. In addition, in time-resolved fluorescence measurement methods or fluorescence measurement methods similar thereto, a variety of labeled anti-S38AA antibodies and other necessary components may be included in the structure.
[0367] As the kit of the present invention, for example, the following can be mentioned. The antibody contained in the following kit can be labeled (for example, labeled with peroxidase, biotin, etc.). When the antibody is not labeled, a labeled antibody containing the antibody labeled by binding to the antibody can be separately contained.
[0368] 1) One or two "antibodies that specifically recognize a short fragment of S38AA", washing solution, color development reagent, reaction quenching solution, dilution buffer and standard solution;
[0369] 2) one or two "antibodies recognizing the N-terminal region of the long S38AA fragment", one or two "antibodies recognizing the C-terminal region of the long S38AA fragment (i.e., antibodies recognizing the C-terminal region common to the long S38AA fragment and the short S38A fragment)", washing solution, color development reagent, reaction quenching solution, dilution buffer and standard solution;
[0370] 3) "a first antibody specifically recognizing a short fragment of S38AA", "a second antibody specifically recognizing a short fragment of S38AA", a washing solution, a color developing reagent, a reaction quenching solution, a dilution buffer and a standard solution;
[0371] 4) "a first antibody that recognizes the N-terminal region of the long S38AA fragment" and a "second antibody that specifically recognizes the long S38AA fragment", one or two "antibodies that recognize the C-terminal region of the long S38AA fragment (i.e., antibodies that recognize the C-terminal region common to the long S38AA fragment and the short S38A fragment), washing solution, color development reagent, reaction quenching solution, dilution buffer and standard solution.
[0372] As used herein, the “antibody that specifically recognizes a short fragment of S38AA”, the “first antibody that specifically recognizes a short fragment of S38AA” and the “second antibody that specifically recognizes a short fragment of S38AA” are preferably Antibody A, Antibody B and Antibody C.
[0373] As used herein, the "antibody recognizing the N-terminal region of the S38AA long fragment" and the "first antibody recognizing the N-terminal side region of the S38AA long fragment" are preferably "antibodies for long fragments".
[0374] As used herein, “antibodies that recognize the C-terminal region of the S38AA long fragment (i.e., antibodies that recognize the C-terminal region common to the S38AA long fragment and the S38AA short fragment)” preferably include antibody A, antibody B, and antibody C. Examples of anti-S38AA long fragment antibodies and anti-S38AA short fragment antibodies that can specifically detect the S38AA long fragment and the S38AA short fragment include the antibodies described in detail in “2. Antibodies of the present invention”.
[0375] 5. Method of the present invention
[0376] (1) Identification and testing methods for Alzheimer's disease
[0377] As mentioned above, the present inventors have first discovered that the amount of the S38AA long fragment produced by cleavage in the extramembrane portion of S38AA increases in the blood of AD patients, and further, in the blood of AD patients, an enzyme that specifically cleaves the long fragment exists, or the activity of the enzyme is high, and the amount of the S38AA short fragment produced by direct cleavage in the extramembrane portion of S38AA significantly increases, and the amount of the S38AA short fragment in the blood increases regardless of whether the severity of Alzheimer's disease (progression of cognitive dysfunction) is mild, moderate, or severe, and it is higher in moderate and severe than in mild. Therefore, they have discovered that the amount of the S38AA short fragment is extremely highly reliable as a highly accurate indicator for determining the onset of Alzheimer's disease and a person at risk of the disease, and as an indicator for determining the degree of progression of Alzheimer's disease.
[0378] Therefore, the present invention provides a method for determining Alzheimer's disease, such as mild or moderate or severe Alzheimer's disease, comprising detecting a short fragment of S38AA in a sample collected from a test animal.
[0379] The determination method of the present invention can determine not only whether a person has Alzheimer's disease and whether he is currently very likely to have the disease, but also whether the person has a high possibility of having the disease in the near future although the person has not yet had the disease.
[0380] The present invention also provides a method for testing the likelihood of currently having Alzheimer's disease or the likelihood of having Alzheimer's disease in the future, the method comprising detecting the S38AA short fragment in a sample collected from a test animal.
[0381] The aforementioned determination of likelihood and testing (results) can at least be used to assist doctors in making a definitive diagnosis of Alzheimer's disease.
[0382] The determination and testing method of the present invention is characterized by detecting the S38AA short fragment in the sample collected from the test animal. In addition, the determination and testing method of the present invention may include the following as specific steps, for example, (i) a step of quantifying the S38AA short fragment in the sample collected from the test animal, and (ii) a step of comparing the amount of the S38AA short fragment quantified in (i) with the amount of the S38AA short fragment in the sample collected from the healthy animal (hereinafter referred to as "control value").
[0383] As a result of the comparison in (ii), when the amount of the S38AA short fragment quantified in (i) is higher than the control value, it indicates that the aforementioned test animal suffers from Alzheimer's disease, is currently likely to suffer from Alzheimer's disease, or is likely to suffer from Alzheimer's disease in the future.
[0384] Furthermore, in addition to the above steps, the determination and testing method of the present invention may further include, based on the result of (ii), a step of determining that the aforementioned test animal suffers from Alzheimer's disease or is currently likely to suffer from Alzheimer's disease or is likely to suffer from Alzheimer's disease in the future when the amount of the S38AA short fragment quantified in (i) is higher than the control value.
[0385] In addition, the present invention provides a method for assisting in determining the progression of Alzheimer's disease, because as described above, the value of the S38AA short fragment in the blood increases regardless of whether the severity of Alzheimer's disease (progression of cognitive dysfunction) is mild, moderate, or severe, and further, it is higher in moderate and severe than in mild.
[0386] The method for assisting determination of the present invention characteristically detects the S38AA short fragment in a sample collected from a test animal. The method for assisting determination of the present invention may include as specific steps, for example, (i) a step of quantifying the S38AA short fragment in a sample collected from a test animal suffering from or likely to suffer from Alzheimer's disease, and (ii) a step of comparing the amount of the S38AA short fragment quantified in (i) with the amount of the S38AA short fragment in a sample collected from the test animal in the past (hereinafter referred to as a "control value").
[0387] As a result of the comparison in (ii), when the amount of the S38AA short fragment quantified in (i) is higher than the control value, it indicates that the Alzheimer's disease in the aforementioned test animal is progressing or the possibility of suffering from Alzheimer's disease is high, and when the amount is less than the control value, it indicates that the Alzheimer's disease in the aforementioned test animal is improving or the possibility of not suffering from Alzheimer's disease is high.
[0388] In addition to the above steps, the steps for assisting the determination method of the present invention may also include: (iii) based on the result of (ii), when the amount of the S38AA short fragment quantified in (i) is higher than the control value, determining that the Alzheimer's disease in the aforementioned test animal is progressing, and when the amount is less than the control value, determining that the Alzheimer's disease in the aforementioned test animal is improving.
[0389] In addition, the present invention also provides a method for evaluating the effect of treatment on a patient under treatment for Alzheimer's disease or a person at risk of Alzheimer's disease who is treated to prevent Alzheimer's disease, because as described above, the amount of S38AA short fragments in the blood increases regardless of whether the severity of Alzheimer's disease (progression of cognitive dysfunction) is mild, moderate or severe, and is higher in moderate and severe than in mild.
[0390] The method for evaluating the therapeutic effect of the present invention is also characterized by detecting the S38AA short fragment in the sample collected from the test animal. In addition, the method for evaluating the therapeutic effect of the present invention may include, for example, the following as specific steps: (i) a step of quantifying the S38AA short fragment in the sample collected from the test animal that has started drug treatment for Alzheimer's disease or drug treatment for preventing the onset of Alzheimer's disease, and (ii) a step of comparing the amount of the S38AA short fragment quantified in (i) with the amount of the S38AA short fragment in the sample collected from the test animal (a sample collected before the start of drug treatment, a sample collected after the start of drug treatment and before the collection in (i)) (hereinafter referred to as the "control value").
[0391] As a result of the comparison in (ii), it is shown that when the amount of the S38AA short fragment quantified in (i) is higher than the control value, the current drug treatment (or the selected therapeutic drug) is not effective, and when the amount is less than the control value, the current drug treatment (or the selected therapeutic drug) is effective.
[0392] In addition to the above steps, the method for evaluating the therapeutic effect of the present invention may also include a (iii) step: determining based on the result of (ii) that when the amount of the S38AA short fragment quantified in (i) is higher than the control value, the current drug treatment (or the selected therapeutic drug) is not effective, and when it is less than the control value, the current drug treatment (or the selected therapeutic drug) is effective.
[0393] In this specification, the therapeutic drug used for drug therapy is a concept that includes not only approved and marketed therapeutic drugs, but also clinical trial drugs under clinical testing. The method for evaluating the therapeutic effect of the present invention can also be used to monitor the efficacy of drugs in clinical testing, etc.
[0394] Although animals that can be test subjects for the method of the present invention are not particularly limited as long as they express S38AA, for example, mammals (e.g., humans, monkeys, cows, pigs, horses, dogs, cats, sheep, goats, rabbits, hamsters, guinea pigs, mice, rats, etc.), birds (e.g., chickens, etc.), etc. are mentioned. Preferred are mammals, and more preferably humans.
[0395] Although the biological sample derived from the test animal to be used as a sample is not particularly limited, there can be mentioned, for example, blood, serum, plasma, saliva, tears, urine, cerebrospinal fluid, etc. More preferred is plasma or cerebrospinal fluid.
[0396] Serum and plasma can be prepared by collecting blood from a test animal according to a conventional method, and separating the liquid components. Cerebrospinal fluid can be collected by known means, such as spinal tap and the like.
[0397] The S38AA long fragment and the S38AA short fragment in the sample can be detected (quantified) by known methods. They can be detected by, for example, Western blotting, gel electrophoresis (e.g., SDS-PAGE, two-dimensional gel electrophoresis, etc.), various separation and purification methods (e.g., ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, affinity chromatography, reverse phase chromatography, isoelectric chromatography, capillary electrophoresis, etc.), ionization methods (e.g., electron impact ionization method, field desorption method, secondary ionization method, fast atom bombardment, matrix-assisted laser desorption / ionization (MALDI) method, electrospray ionization method, etc.), mass spectrometer (e.g., double focusing mass spectrometer, quadrupole mass spectrometer, time-of-flight mass spectrometer, Fourier transform mass spectrometer, ion cyclotron mass spectrometer, etc.), etc. The method of the present invention also includes detection (quantification) using a measuring device that applies these measuring principles.
[0398] In addition, the S38AA long fragment and the S38AA short fragment can also be detected (quantified) by a known immunochemical method (turbidimetry, competition method, immunoassay method, chemifluorescence method, chemifluorescence electron method, sandwich method, etc.). Regarding these immunochemical methods, for example, reference can be made to "Radioimmunoassay" edited by Hiroshi Irie (Kodansha, published in 1974), "radioimmunoassay (sequel)" edited by Hiroshi Irie (Kodansha, published in 1979), "Enzyme Immunoassay" edited by Eiji Ishikawa et al. (3rd edition, Igaku-Shoin, published in 1987), "Methods in ENZYMOLOGY" Vol. 121 (Immunochemical Techniques (Part I: Hybridoma Technology and Monoclonal Antibodies)) (published by Academic Press), etc.
[0399] As a specific detection (quantification) method for S38AA long fragments and S38AA short fragments, the amount of S38AA short fragments can be quantified by subtracting the measured value of the S38AA long fragment sample obtained using a single "antibody recognizing the N-terminal side region of the S38AA long fragment" or a combination of "antibody recognizing the N-terminal side region of the S38AA long fragment" and "antibody recognizing the C-terminal side region of the S38AA long fragment" from the measured values of the S38AA long fragments and S38AA short fragments in the sample (which uses an "antibody that recognizes the C-terminal side region common to the S38AA long fragment and the S38A short fragment"), or the measured value obtained by a similar method can be quantified as the ratio of the amount of the S38AA short fragment to the amount of the S38AA long fragment, or the amount of the S38AA short fragment can be directly quantified using the "antibody that specifically recognizes the S38AA short fragment" of the present invention. Examples of the anti-S38AA long fragment antibody and the anti-S38AA short fragment antibody capable of specifically detecting the S38AA long fragment and the S38AA short fragment include the antibodies described in detail in "2. Antibodies of the present invention".
[0400] As used herein, the “antibody that recognizes the C-terminal side region common to the S38AA long fragment and the S38A short fragment” is preferably antibody A, B or C.
[0401] The "antibody that recognizes the N-terminal region of the S38AA long fragment" is preferably an "antibody for the long fragment".
[0402] The "antibody that recognizes the C-terminal region of the S38AA long fragment" is preferably antibody A, B or C.
[0403] The "antibody that specifically recognizes the short fragment of S38AA" is preferably antibody A, B or C.
[0404] As a measuring method in the present invention, for example, "long ELISA" can be mentioned. "Long ELISA" is a method for detecting (quantifying) the amount of S38AA long fragment, and is characteristically a sandwich ELISA method using "antibodies for long fragments" and "at least one antibody selected from antibodies A, B and C".
[0405] As a measuring method in the present invention, for example, "total ELISA" can be mentioned. "Total ELISA" is a method for detecting (quantifying) "the total amount of S38AA long fragment and S38AA short fragment", and is characteristically a sandwich ELISA method using "at least two antibodies selected from antibodies A, B and B".
[0406] As the “method for detecting (quantifying) the amount of the S38AA short fragment” in the present invention, there can be mentioned a method comprising subtracting the “measurement result (quantitative value) of the long ELISA” from the above-mentioned “measurement result (quantitative value) of the total ELISA”.
[0407] As the "control value" used in the method of the present invention, the amount of the S38AA short fragment in the control sample, or the amount of the S38AA short fragment measured or set in advance for the control, etc., can be used. This value does not need to be measured simultaneously with the method of the present invention.
[0408] In order to set the control value here, a plurality of individuals may be used as controls, and the average of the measured values of the plurality of individuals may be used as the control value. That is, the scope of the method of the present invention also encompasses the above-mentioned determination and the like using the amount of the S38AA short fragment in a control sample derived from a control group (healthy animals, animals with Alzheimer's disease of a certain degree of progression, etc.) as a control value.
[0409] For example, when a sample derived from a healthy animal is used as a control sample, it can be judged or determined that a human currently suffers from Alzheimer's disease or has a high possibility of suffering from Alzheimer's disease, or has a possibility of suffering from Alzheimer's disease in the future.
[0410] In addition, when a sample derived from an animal with Alzheimer's disease at a specific degree of progression is used as a control sample, when the amount of the S38AA short fragment in the test sample is higher than that in the control sample, it can be judged or determined that the degree of progression of Alzheimer's disease is higher than that of the control animal suffering from the disease.
[0411] Furthermore, when a sample collected from a test animal from which the test sample was collected in the past is used as a control sample, when the amount of the S38AA short fragment in the test sample is higher than that in the control sample, it can be determined that Alzheimer's disease is progressing, and when the amount is lower than that in the control sample, it can be determined that the disease is improving.
[0412] Furthermore, using multiple control samples, such as control samples derived from animals with Alzheimer's disease, control samples derived from healthy animals, and the like, a person at risk of Alzheimer's disease, i.e., a person in whom accumulation of Aβ and tau proteins has already begun and who is very likely to develop Alzheimer's disease in the near future (even if the onset of the disease cannot be clearly diagnosed), can be identified by using an index in which the amount of S38AA short fragments in the test sample is greater than the amount of S38AA short fragments in the control sample derived from a healthy animal and less than the amount of S38AA short fragments in the control sample derived from an animal with Alzheimer's disease.
[0413] In addition, using a sample collected in the past from a test animal from which a test sample was collected and for which drug treatment for Alzheimer's disease has been started as a control sample, when the amount of the S38AA short fragment in the test sample is higher than the amount in the control sample, it can be evaluated that the current drug treatment is not effective, and when the amount is lower than the amount in the control sample, it can be evaluated that the drug treatment is effective.
[0414] When the "amount of the polypeptide of SEQ ID NO: 1 in the sample collected from the test animal" is greater than the "amount of the polypeptide of SEQ ID NO: 1 in the sample collected from the healthy animal (control value)", it can be determined that the test animal currently suffers from Alzheimer's disease or the possibility that the animal may suffer from Alzheimer's disease in the future.
[0415] The amount of "the polypeptide of SEQ ID NO: 1 in the sample collected from the test animal" is preferably 1.1 to 10 times the control value. It is more preferably 1.1 to 8 times the control value. It is further preferably 1.2 to 5 times the control value. It is most preferably 1.2 to 3 times the control value.
[0416] When "the polypeptide of SEQ ID NO: 1 in the sample collected from the test animal" is greater than "the amount of the aforementioned polypeptide in the sample collected from the test animal in the past (control value)", it can be determined that Alzheimer's disease in the test animal is progressing.
[0417] The amount of "the polypeptide of SEQ ID NO: 1 in the sample collected from the test animal" is preferably 1.1 to 10 times the control value. It is more preferably 1.1 to 8 times the control value. It is further preferably 1.2 to 5 times the control value. It is most preferably 1.2 to 3 times the control value.
[0418] When "the amount of the polypeptide of SEQ ID NO: 1 in the sample collected from the test animal" is less than the amount of the aforementioned polypeptide in the sample collected from the test animal in the past (control value)", it can be determined that Alzheimer's disease in the test animal is improving.
[0419] The amount of "the polypeptide of SEQ ID NO: 1 in the sample collected from the test animal" is preferably 0.1 to 0.9 times the control value. It is more preferably 0.2 to 0.9 times the control value. It is further preferably 0.3 to 0.9 times the control value. It is most preferably 0.4 to 0.9 times the control value.
[0420] The quantitative analysis of the S38AA short fragment can be performed by standardizing the amount of the S38AA short fragment in the sample with the amount of the standard protein (internal standard protein). That is, after the amount of the S38AA short fragment in the sample and the amount of the standard protein are quantified by using the above method, the signal ratio of the two (S38AA short fragment / standard protein) is calculated, and the amount of the S38AA short fragment in the sample can be expressed as a ratio to the abundance of the standard protein.
[0421] The standard protein may be a protein constitutively expressed in a given amount, and proteins commonly expressed in many tissues and cells are preferred. For example, proteins essential for cell survival may be mentioned, such as proteins encoded by genes, such as RNA synthases, energy-generating enzymes, ribosomal proteins, cytoskeletal proteins, etc. (housekeeping genes). Specific examples thereof include, but are not limited to, proteins such as β-actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-tubulin, etc. Particularly preferred is β-actin.
[0422] In addition, instead of the aforementioned control value, a cutoff value of the amount of S38AA short fragments in the blood associated with Alzheimer's disease or mild cognitive impairment may be set in advance, and the amount of S38AA short fragments in the blood of the test animal may be compared with the cutoff value.
[0423] For example, when the amount of the S38AA short fragment in the blood of the test animal is not less than the cutoff value, it can be determined that the test animal has Alzheimer's disease, is currently likely to have Alzheimer's disease, or is likely to have Alzheimer's disease in the future.
[0424] The "cutoff value" is a value that satisfies high diagnostic sensitivity (true positive rate) and high diagnostic specificity (true negative rate) when the disease is determined using the value as a criterion. For example, a value showing a high positive rate in individuals who have developed Alzheimer's disease and a high negative rate in individuals who have not developed Alzheimer's disease can be set as a cutoff value.
[0425] The method for calculating the cut-off value is well known in the art. For example, the amount of the S38AA short fragment in the blood of individuals who develop Alzheimer's disease and individuals who do not develop Alzheimer's disease is calculated, and the diagnostic sensitivity and diagnostic specificity of the calculated value are obtained. Based on these values, a ROC (receiver operating characteristic) curve is created using commercially available analysis software. Then, a value as close to 100% as possible for diagnostic sensitivity and diagnostic specificity is obtained, and this value can be used as a cut-off value. In addition, for example, the "mean + 2 standard deviations" of the amount of the S38AA short fragment in the blood of a large number of healthy animals is preferably set as a cut-off value. Using this value, it is possible to determine the development of Alzheimer's disease with good sensitivity and specificity. In addition, for example, by obtaining the value that maximizes the likelihood ratio between diagnostic sensitivity and diagnostic specificity from the ROC curve and using this value as a cut-off value, Alzheimer's disease can be determined with high sensitivity. Alternatively, the point with the lowest diagnostic ability on the ROC curve, that is, the point farthest from the line with an area under the ROC curve of 0.5, is set as the cutoff value, that is, "sensitivity + specificity - 1" is calculated, and the point where this value becomes the maximum is preferably set as the cutoff value.
[0426] The cutoff value of the amount of the S38AA short fragment transformed with the recombinant protein of the present specification is, for example, 45-75 units. The cutoff value is preferably, for example, 49-69 units. The cutoff value is more preferably, for example, 54-64 units. The cutoff value is more preferably, for example, 56-62 units. The cutoff value is further preferably, for example, 58-61 units. The cutoff value is most preferably, for example, 59 units.
[0427] Another preferred value for the cutoff includes 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 and 75 units.
[0428] The cutoff value for the amount of the S38AA short fragment contained in the body is, for example, 45-75 ng / mL. The cutoff value is preferably, for example, 49-69 ng / mL. The cutoff value is more preferably, for example, 54-64 ng / mL. The cutoff value is more preferably, for example, 56-62 ng / mL. The cutoff value is further preferably, for example, 58-61 ng / mL. The cutoff value is most preferably, for example, 59 ng / mL.
[0429] Another preferred value for the cutoff includes 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, and 75 ng / mL.
[0430] When Alzheimer's disease is determined by the method of the present invention, in addition to the S38AA short fragment, changes in other diagnostic markers of Alzheimer's disease can also be examined. Other diagnostic markers of Alzheimer's disease include, for example, known markers such as Aβ, homocysteine, neurofilaments, various inflammation-related proteins (C-reactive protein, IL-1β, TNF, IL-6 and TGFβ), cholesterol, tau, phosphorylated tau, etc., which have been studied for their potential as plasma biomarkers. These can be detected according to conventional well-known detection methods.
[0431] (2) Methods for treating and preventing Alzheimer's disease
[0432] When the above-mentioned method for determining Alzheimer's disease of the present invention, etc. determines that the test animal suffers from Alzheimer's disease, or is currently likely to suffer from Alzheimer's disease, or is likely to suffer from Alzheimer's disease in the future, Alzheimer's disease can be treated or prevented as follows: based on the result, determining a therapeutic or preventive drug for Alzheimer's disease to be administered to the test animal, and administering a therapeutically effective amount of the therapeutic or preventive drug to the test animal.
[0433] In this specification, "therapeutic drugs for Alzheimer's disease" include not only drugs aimed at permanently curing Alzheimer's disease but also drugs aimed at inhibiting the progression of Alzheimer's disease, for example. Drugs aimed at inhibiting the progression can be used as "preventive drugs for Alzheimer's disease".
[0434] Examples of the therapeutic drug for Alzheimer's disease include cholinesterase inhibitors, NMDA receptor antagonists, amyloid β protein removers and production inhibitors, and tau protein removers and production inhibitors.
[0435] Examples of the cholinesterase inhibitor include donepezil, galantamine, rivastigmine, huperzine A, and tacrine.
[0436] Examples of the NMDA receptor antagonist include memantine.
[0437] Examples of the amyloid beta remover and production inhibitor include amyloid beta vaccine, amyloid beta removal antibody, amyloid beta production enzyme inhibitor, amyloid beta coagulation inhibitor and amyloid beta degradation promoter. Specific examples include CNP-520, E-2609, aducanumab, solazumab, gantenerumab, crenezumab, amilomotide, ASD-005, HSH-971, ELND-005, ALZT-OP1, nilvadipine, ACI-24, UB-311, AFFITOPE AD-02, LY-3002813, BAN-2401, Neurostem-AD, CT-1812, ID-1201, NIC5-15, BI-425809, Posiphen, PQ-912, Bryostatin-1, Apabetalone, PBT-2, RIV-1061-IR, MEDI-1814, PF-05236812, SAR-228810, Lu-AF20513, PRI-002, IRX-4204, GC-021109, AAD-2004, CTS-21166, LY-3323795, benfotiamine, bisnorcymserine, MDR-1339, KHK-6640, and NPT-088.
[0438] Examples of the tau protein remover and the inhibitor include tau protein vaccine, tau protein removal antibody, tau protein modification inhibitor, tau protein coagulation inhibitor and tau protein hydrolysis promoter. Specific examples include TRx-237, TPI-287, ABBV-8E12, RG-6100, AADvac1, RO7105705, PTI-80, JNJ-63733657, UCB-0107, BIIB-076, MC-1, ACI-35 and AZP-2006.
[0439] The above therapeutic drugs can be used in appropriate combination according to the patient's symptoms.
[0440] 6. Therapeutic drugs of the present invention
[0441] The above-mentioned therapeutic drugs for Alzheimer's disease that can be used vary depending on the severity of the symptoms (mild, moderate, severe, etc.). Therefore, the determination result of the method for assisting in determining the degree of progression of Alzheimer's disease of the present invention described above can be used to determine the therapeutic drug to be administered to the test animal. Therefore, the present invention provides a therapeutic drug for Alzheimer's disease for a test animal (patient) whose degree of progression of Alzheimer's disease has been determined.
[0442] As described above, the amount of S38AA short fragments in the blood of AD patients increases significantly, and there is a positive correlation between the amount of S38AA long fragments in the blood and the severity of Alzheimer's disease (progression of cognitive dysfunction). Therefore, the present invention provides a therapeutic or preventive drug for Alzheimer's disease, which contains the following as an active ingredient: a drug that reduces the amount of S38AA short fragments in the body of a patient with Alzheimer's disease or a patient (human) who may suffer from Alzheimer's disease, or a drug that inhibits the production of S38AA short fragments in the body of a patient with Alzheimer's disease or a patient (human) who may suffer from Alzheimer's disease. As used herein, the amount of S38AA short fragments in the body of a patient with Alzheimer's disease or a patient who may suffer from Alzheimer's disease is, for example, the amount of S38AA short fragments contained in the biological tissue or body fluid of the patient or the patient who may suffer from Alzheimer's disease. Specifically, blood, cerebrospinal fluid, urine, saliva, tears, etc. can be mentioned.
[0443] The drug that reduces the amount of S38AA short fragments is, for example, a neutralizing antibody, and it can reduce the free S38AA short fragments in the body by binding to the S38AA short fragments in the body of a patient or a patient who may have Alzheimer's disease. The drug that inhibits the production of S38AA short fragments is, for example, an inhibitor of an enzyme that produces 38AA short fragments by cleaving S38AA long fragments, and each of them can be obtained by methods known to those skilled in the art.
[0444] 7. Method for screening candidate substances for treating or preventing Alzheimer's disease
[0445] The present invention provides a method for selecting a candidate substance for a therapeutic or preventive drug for Alzheimer's disease by using whether a test substance removes S38AA short fragments or whether it inhibits the production of S38AA short fragments as an index, and a substance obtained by the method. In the screening method of the present invention, a substance that reduces the amount of S38AA short fragments in blood or downregulates the production of S38AA short fragments is selected as a candidate substance for a therapeutic or preventive drug for Alzheimer's disease.
[0446] The test substance to be subjected to the screening method of the present invention can be any known or novel compound. Examples thereof include nucleic acids, carbohydrates, lipids, proteins, peptides, organic low molecular weight compounds, compound libraries generated using combinatorial chemistry techniques, random peptide libraries, natural components derived from microorganisms, animals and plants, marine organisms, etc.
[0447] For example, the screening methods of the present invention may include:
[0448] (i) a step of contacting a test substance with cells that allow measurement of production of S38AA short fragments; (ii) a step of measuring the amount of S38AA short fragments produced in the cells contacted with the test substance and comparing the amount with the amount of S38AA short fragments produced in control cells not contacted with the test substance; and (iii) a step of selecting the test substance that downregulates the amount of S38AA short fragments produced as a candidate substance for a therapeutic or preventive drug for Alzheimer's disease based on the comparison result of the above (ii).
[0449] In addition, the screening method of the present invention may include:
[0450] (i) a step of contacting a test substance with an enzyme that forms a short S38AA fragment; (ii) a step of measuring the amount of S38AA short fragment produced in the enzyme contacted with the test substance and comparing the amount with the amount of S38AA short fragment produced in a control enzyme that is not contacted with the test substance; and (iii) a step of selecting a test substance that downregulates the amount of S38AA short fragment produced as a candidate substance for a therapeutic or preventive drug for Alzheimer's disease based on the comparison result of the above (ii). The above enzyme substrate is not particularly limited as long as it produces a short S38AA fragment, and, for example, S38AA, a long S38AA fragment, a S38AA fragment, etc. can be mentioned.
[0451] In addition, for example, the method may include (i) contacting a test substance with a S38AA short fragment, (ii) measuring the amount of free S38AA short fragments remaining after contact with the test substance and comparing the amount with the amount of the free S38AA short fragments when the free S38AA short fragments are not contacted with the test substance, and (iii) selecting a test substance that downregulates the amount of free S38AA short fragments by binding to the S38AA short fragments as a candidate substance for a therapeutic or preventive drug for Alzheimer's disease based on the comparison result of the above (ii). The method may be performed by adding the test substance to a system containing an enzyme that produces the above S38AA short fragments and its substrate, or adding the test substance to a system containing a pre-prepared S38AA short fragment. Alternatively, in the step (i) of contacting the test substance with the S38AA short fragments, the S38AA short fragments may form a precipitate (e.g., immunoprecipitation, etc.) due to the contact.
[0452] The "cell" to be used in the screening method of the present invention means a cell that allows the evaluation of the level of production of the target S38AA short fragment. Examples of cells include cells that can naturally produce the target S38AA short fragment, S38AA-expressing cells that can produce the S38AA short fragment by stimulation, and genetically engineered cells that can produce the S38AA short fragment.
[0453] There is no particular limitation on cells that can naturally produce S38AA short fragments, and as such cells, primary cultured cells of mammals (e.g., humans, mice, etc.), cell lines induced from the primary cultured cells, etc. can be used. S38AA is known to be expressed in U251 cells and SHSY-5Y cells, and is also expressed in BE(2)-C cells and SK-N-MC cells. In addition, genetically engineered cells that overexpress S38AA or S38AA tagged with a FLAG tag, etc. can also be produced using known techniques. By culturing, S38AA is cleaved from cells expressing S38AA, and S38AA short fragments are released. When the amount of S38AA short fragments produced is small, the production of S38AA short fragments can be measured by appropriately culturing under conditions that easily cause cleavage of S38AA. Examples of conditions that easily cause cleavage of S38AA include culturing in a glucose-depleted medium or a medium containing a substance known to physiologically stimulate the brain. Specific examples of such substances include cytokines such as TNFα, interferon-γ, interleukin-1, interleukin-6, etc., amyloid β or its aggregates, and the like.
[0454] The test substance and the cells that allow the measurement of the production of the S38AA short fragment are contacted in a culture medium. The culture medium is appropriately selected according to the cells that allow the measurement of the production of the S38AA short fragment. Examples thereof include minimal essential medium (MEM), Dulbecco's modified Eagle medium (DMEM) containing about 5-20% fetal bovine serum, and the like. The culture conditions are appropriately determined in the same manner. For example, the pH of the culture medium is about 6 to about 8, the culture temperature is generally about 30 to about 40° C., and the culture time is about 0.1 to about 72 hours.
[0455] The contact between the test substance and the enzyme that forms the S38AA short fragment is carried out in a reaction system containing the enzyme and its substrate. The enzyme concentration, substrate concentration, pH, temperature, etc., as well as the enzyme substrate, reaction time, etc. of the reaction system can be appropriately set.
[0456] As used herein, as an enzyme that produces a short S38AA fragment, a solution containing the enzyme can be used. Examples of the solution include body fluids (plasma, etc.), organ or tissue extracts, cell extracts, etc. that can form a short S38AA fragment.
[0457] The amount of S38AA short fragment produced can be measured by measuring the amount of S38AA short fragment released in a cell culture supernatant or a reaction system according to the method described in the item (5. Method of the present invention).
[0458] The production amount may preferably be compared based on the presence or absence of a significant difference. The production amount of the S38AA short fragment in control cells or enzymes not in contact with the test substance may be measured before or simultaneously with measuring the production amount of the S38AA short fragment in cells or enzymes in contact with the test substance.
[0459] The substance obtained by the screening method of the present invention can be used as a candidate substance for developing a new therapeutic or preventive drug for Alzheimer's disease.
[0460] [Example]
[0461] The present invention is explained in detail below by referring to Examples; however, the present invention is not limited thereto.
[0462] Example 1: Identification of the N-terminal cleavage site of the S38AA long fragment in human plasma
[0463] After separating plasma proteins from AD patients by polyacrylamide gel electrophoresis (SDS-PAGE), a gel fragment containing the S38AA fragment was cut out and analyzed by liquid chromatography-mass spectrometry (LC-MS / MS) after in-gel digestion with trypsin. The measurement data was searched against the MASCOT database, and the N-terminal sequence of the S38AA fragment was determined.
[0464] Specifically, a pooled sample of plasma from some AD patients was applied to a 4-12% Bis-Tris gel (invitrogen) and the proteins were separated by SDS-PAGE (25 mA, 110 min, MOPS buffer). After the gel was stained with Coomassie Brilliant Blue, the band seen at 80-100 kDa was cut out and applied to the digestion process.
[0465] The cut gel fragments were placed in a 96-well microplate, acetonitrile was added, the mixture was centrifuged under reduced pressure, 10 mM DTT / 100 mM NH4HCO3 was added, and incubation was performed. After the solvent was removed, 55 mM ICH2CONH2 / 100 mMNH4HCO3 was added, and the mixture was incubated. After the solvent was removed, 100 mM NH4HCO3 was added, the gel was centrifuged under reduced pressure, 0.1% RapiGest / 25 mM NH4HCO3 was added, and incubation was performed. Then, the mixture was centrifuged and dried under reduced pressure, an enzyme solution (50 mM NH4HCO3, 12.5 ng / μL trypsin) was added, and enzymatic digestion was performed. After the reaction, the peptide solution was transferred to another 96-well microplate, a mixed solvent of acetonitrile:milliQ:trifluoroacetic acid (TFA) = 500:500:1 was added to the gel, and the obtained peptide extract was concentrated under reduced pressure. TFA was added thereto, and the mixture was concentrated under reduced pressure to give a sample for MS analysis.
[0466] The obtained samples were analyzed by LC-MS / MS. When the data obtained by the Orbitrap mass spectrometer were subjected to a MASCOT database search of the amino acid sequence of the S38AA protein, multiple peptide fragments were identified in the amino acid sequence of the S38AA protein ( Figure 1 ). Among these sequences, the peptide closest to the N-terminal side is the 399th to 413th amino acid sequence, and an MS / MS spectrum showing this sequence was observed ( Figure 2 ). This cleavage site is on the C-terminal side of the 398th serine (S). Regarding the cleavage by the digestive enzyme trypsin, since this enzyme specifically cleaves the C-terminus of lysine (K) or arginine (R), and the cleavage reaction does not occur on the C-terminal side of the serine (S) of the fragment, it is suggested that cleavage has been performed at this site. Detection of the peptide fragment revealed that the N-terminal side of the purified S38AA fragment was cleaved at S / E positions 398 to 399. The S38AA fragment identified here is referred to as the S38AA long fragment.
[0467] Example 2: Identification of the N-terminal cleavage site of the S38AA short fragment in human plasma
[0468] After removing the S38AA long fragment by an immunoprecipitation method using a rabbit-derived anti-S38AA polyclonal antibody (also referred to as "MBL," "antibody for S38AA long fragment," or "antibody for long fragment") that recognizes the N-terminus of the S38AA long fragment, the S38AA long fragment was removed using a mouse-derived anti-S38AA monoclonal antibody A (using a partial peptide of the C-terminal amino acid sequence of the S38AA fragment as an immunogen, establishing an antibody-producing hybridoma, and isolating and purifying it; antibody A), and a mouse-derived anti-S38AA monoclonal antibody B (using a partial peptide of the C-terminal amino acid sequence of the S38AA fragment as an immunogen). A partial peptide of the C-terminal amino acid sequence of the 8AA fragment was used as an immunogen to establish an antibody-producing hybridoma, which was separated and purified; antibody B), or a mouse-derived anti-S38AA monoclonal antibody C (a recombinant protein of the long fragment of S38AA in Escherichia coli was used as an immunogen to establish an antibody-producing hybridoma, which was separated and purified; antibody C), the remaining S38AA fragment was immunoprecipitated, and its fractions were purified by a reverse phase column, digested with trypsin, analyzed by LC-MS / MS, and the N-terminal sequence of the S38AA fragment was determined.
[0469] Specifically, PBS containing protease inhibitors (cOmpleteTablets Mini, Roche) is added to the combined mixture of the plasma of AD patients, and protein G Mag Sepharose Xtra (beads, GEHEALTHCARE) is further added and mixed to remove endogenous immunoglobulins. After removing the beads, the antibody for long fragments is added to the supernatant, and antigen-antibody reaction is performed. After mixing, beads are newly added, and the recovered protein containing the antibody for long fragments and the S38AA long fragment adsorbed to the antibody is removed. The aforementioned antibody A, B or C is added to the supernatant after removing the beads, and antigen-antibody reaction is performed. After mixing, beads are newly added, and beads are collected to obtain antibodies and the S38AA fragment adsorbed on the antibody. 8M urea / 1% TFA solution is added to the beads recovered by immunoprecipitation, and the S38AA fragment is eluted. The obtained solution containing the S38AA fragment was concentrated, and the total amount was separated by a reverse phase column (ZORBAX 300SB-C3, 4.6x150 mm, with a guard column, Agilent). The separation conditions are shown in Table 1 below. Each fraction obtained was measured by sandwich ELISA using two antibodies recognizing the C-terminal side region of the S38AA fragment, and the fraction containing the S38AA fragment was digested with an enzyme solution (1M NH4HCO3, 10 mM CaCl2, 1ng / μL trypsin), and the obtained peptides were concentrated with GL-tip SDB and GL-Tip GC (GLSciences).
[0470] The peptides obtained were analyzed by LC-MS / MS. When the data obtained by the Q-Exactive HF mass spectrometer were subjected to a MASCOT database search of the amino acid sequence of the S38AA protein, S38AA was identified with the highest score, and multiple peptide fragments were identified ( Figure 3 ). Among these sequences, the peptide closest to the N-terminal side is the 617th to 627th sequence, and an MS / MS spectrum showing this sequence was observed ( Figure 4 ). The cleavage site is on the C-terminal side of the 616th asparagine (N). Regarding the cleavage by the digestive enzyme trypsin, since the enzyme specifically cleaves the C-terminus of lysine (K) or arginine (R), and the cleavage reaction does not occur on the C-terminal side of the asparagine (N) of the fragment, it is shown that cleavage has been performed at this site. Detection of the peptide fragment revealed that the purified S38AA fragment was cleaved at the 617th to 618th N / G. The S38AA fragment identified here is referred to as the S38AA short fragment.
[0471] [Table 1]
[0472] Table 1 Reverse phase column purification and separation conditions
[0473]
[0474] Example 3: Identification of the C-terminal cleavage site of the S38AA long fragment in human plasma
[0475] The S38AA long fragment was separated by an antibody column purification method using the "rabbit-derived polyclonal antibody to the S38AA long fragment (antibody for the long fragment)" used in Example 2, and the gel fragment containing the S38AA long fragment was cut out and analyzed by LC-MS / MS after in-gel digestion with trypsin. The measurement data was searched with the MASCOT database, and the C-terminal fragment sequence of the S38AA long fragment was determined.
[0476] Specifically, 50 mM Tris-HCl / 0.05% Tween-20 (pH 7.4) was added to the mixed sample of the plasma of some AD patients, and the mixture was applied to anion exchange column purification (Hitrap Q FF, GE HEALTHCARE). In succession, it was eluted with 50 mM phosphoric acid / 0.05% Tween-20 / 500 mM NaCl (pH 7.4). The eluted fraction was applied to a column (HiTrap NHS-activated HP column, GE HEALTHCARE) bound to an antibody for long fragments. The column was washed with PBS-T and eluted with 0.1 M glycine-HCl / 0.05% Tween-20 (pH 2.7). The eluent was immediately returned to neutrality with 1 M Tris-HCl (pH 9.0). The obtained sample is applied to a HiTrapQ FF column (GE HEALTHCARE) equilibrated with 50 mM Tris-HCl (pH 7.4) in advance, and the surfactant is removed. The sample is concentrated by centrifugation under reduced pressure, 50 mM DTT / LDS buffer is added, and the mixture is heated. The total amount of the sample is applied to a 4-12% Bis-Tris gel (Invitrogen), and separated by SDS-PAGE (50 mA, 90 min, MOPS buffer). After dyeing the gel with Sypro Ruby (pierce), the band seen at 80-100 kDa is cut out and applied to the digestion process.
[0477] The excised gel was placed in a 96-well microplate, acetonitrile was added, and sonication was performed. Thereafter, the mixture was centrifuged and dried under reduced pressure, 10 mM DTT / 25 mM NH4HCO3 was added, and incubation was performed. After removing the solvent, 55 mMICH2CONH2 / 25 mM NH4HCO3 was added, and incubation was performed under light shielding. After removing the solvent, 50 mM NH4HCO3 was added, the mixture was incubated, acetonitrile was added, and sonication was performed. After removing the solvent, the gel was centrifuged and dried under reduced pressure, 0.1% RapiGest / 25 mM NH4HCO3 was added, and incubation was performed. Thereafter, the mixture was centrifuged and dried under reduced pressure, incubation was performed, enzyme solution (50 mM NH4HCO3, 5 ng / μL trypsin) was added, and the mixture was incubated. After removing the solvent, 50 mM NH4HCO3 was added, the mixture was incubated, and enzymatic digestion was performed. After the reaction, the peptide solution was transferred to another 96-well microplate, a mixed solvent of acetonitrile: milliQ: TFA = 500:500:1 was added to the gel, and sonication was performed. This operation was repeated again, and the obtained peptide extract was concentrated under reduced pressure to provide a sample for MS analysis.
[0478] The peptides obtained were analyzed by LC-MS / MS. When the data obtained by the Orbitrap mass spectrometer were searched against the MASCOT database for the amino acid sequence of the S38AA protein, multiple peptide fragments were identified in the amino acid sequence of the S38AA protein ( Figure 5 ). Among these sequences, the peptide closest to the C-terminal side is the 1040th to 1049th sequence, and an MS / MS spectrum showing this sequence was observed ( Figure 6 ). The cleavage site is on the C-terminal side of the leucine (L) at position 1049. As for the cleavage by the digestive enzyme trypsin, since the enzyme specifically cleaves the C-terminus of lysine (K) or arginine (R), and the cleavage reaction does not occur on the C-terminal side of the leucine (L) of the fragment, it is suggested that the cleavage has been performed at this site. Detection of peptide fragments revealed that the C-terminus of the S38AA long fragment was cleaved at the L / R at positions 1049 to 1050. Since the S38AA short fragment has the same reactivity as the "antibody recognizing the C-terminus of the S38AA long fragment (antibody A, antibody B or antibody C) used in Example 2, it is believed that the C-terminus of the S38AA short fragment is also cleaved at the same site.
[0479] Example 4: Production of recombinant proteins of S38AA long fragment and S38AA short fragment in E. coli and analysis by ELISA Measure them
[0480] Recombinant proteins of the S38AA long fragment and the S38AA short fragment were produced in E. coli and used as reference standards to construct a long ELISA quantifying only the S38AA long fragment and a total ELISA quantifying both fragments.
[0481] Specifically, a transformant of Escherichia coli BL21 (DE3) was produced, wherein the plasmid DNA of the S38AA long fragment sequence (399-1049 amino acid sequence) and the S38AA short fragment sequence (617-1049 amino acid sequence) was introduced. The culture was continued to be shaken, and the cells were collected by centrifugation. The protein extraction reagent B-PER (Thermo Fisher Scientific) was suspended in a small amount of bacterial bodies, and the centrifuged supernatant was electrophoresed by SDS-PAGE, and the expression of the target protein was confirmed. The bacterial bodies were suspended in buffer A (20 mM Tris HCl pH 8.0, 200 mM NaCl, 10% glycerol, 20 mM imidazole), protease inhibitor cOmplete EDTA-free (Roche) and nuclease Benzonase to destroy the bacterial bodies, and the suspension was centrifuged. Using a 0.22 μm filter, the residual bacterial bodies were removed from the centrifuged supernatant, and Ni affinity purification was performed using HisTrap HP. The eluted fractions of the target protein were combined together and used as reference standards. The protein concentrations of the reference standards were measured to be exactly 1.4 mg / mL (long fragment) and 1.6 mg / mL (short fragment), respectively.
[0482] A sandwich ELISA (long ELISA) by "antibody recognizing the N-terminal side region of the S38AA long fragment (antibody for long fragment used in Example 2)", "antibody A recognizing the C-terminal side region", "antibody B" or "antibody C", and a sandwich ELISA (total ELISA) by two antibodies selected from "antibody A", "antibody B" and "antibody C" that recognize the C-terminal side region common to both the S38AA long fragment and the S38AA short fragment were generated. As a quantitative reference standard, the above-mentioned recombinant protein (standard protein) was prepared in Escherichia coli and measured by two ELISAs. The sample was applied to the plate on which each antibody was fixed and incubated. After washing 3 times, each HRP-labeled antibody was added and incubated. After washing 3 times, a 3% 3,3',5,5'-tetramethylbenzidine (TMB) solution was added, and the mixture was incubated under light shielding. Finally, 8% sulfuric acid was added to terminate the reaction, and the absorbance (OD) at 450 nm was measured. As a result, a standard protein concentration-dependent response was observed, and a good calibration curve was obtained ( Figure 7 ). In the long ELISA, no reaction was observed to the S38AA short fragment standard protein.
[0483] Example 5: Quantification of S38AA long fragment and S38AA short fragment in human plasma (total ELISA-long ELISA subtraction)
[0484] In order to quantify the S38AA long fragment and S38AA short fragment contained in human plasma, quantification was performed by ELISA using the subtraction method.
[0485] Specifically, the aforementioned total ELISA and long ELISA were used to quantify the amount of S38AA short fragments contained in each plasma from 4 healthy subjects and 8 moderate and severe AD patients. Quantification was performed according to the method described in Example 4. A calibration curve for each ELISA was created by measuring the S38AA long fragment standard protein. The amount of S38AA short fragments was calculated by subtracting the quantitative value of the long ELISA from the quantitative value of the total ELISA. As a result, the quantitative values of the S38AA long fragment and the S38AA short fragment in each sample were obtained ( Figure 8 ).
[0486] Based on the obtained results, the amounts of the S38AA short fragment and the S38AA long fragment in the plasma derived from healthy subjects and AD patients were analyzed. As a result, it was found that the amount of the S38AA short fragment was highly distinguishable between healthy subjects and AD patients, and could determine moderate and severe AD patients with high sensitivity compared with the amount of the S38AA long fragment ( Fig. 9 ).
[0487] Example 6: Quantification of S38AA long fragment and S38AA short fragment in human plasma (long fragment immunoprecipitation removal method) Law)
[0488] In order to quantify the S38AA long fragment and S38AA short fragment contained in human plasma, the removal of the S38AA long fragment was performed using an immunoprecipitation method and ELISA quantification.
[0489] Specifically, PBS is added to each mixed sample of the plasma of some healthy subjects and AD patients, and protein G Mag Sepharose Xtra (beads, GE HEALTHCARE) is further added and mixed to remove endogenous immunoglobulins. After the reaction, the polyclonal antibody (antibody for long fragments) of the S38AA long fragment of rabbit origin is added to the supernatant to carry out antigen-antibody reaction. After the reaction, the reaction solution is mixed with new beads, and the antigen-antibody complex is recovered on the beads. By adding 0.1M Gly-HCl (pH 2.8) to the recovered beads, the recovered protein containing the S38AA long fragment is eluted. The eluent is immediately returned to neutrality with 1M Tris-HCl (pH 9.0). The amount of the S38AA long fragment and the S38AA short fragment contained in the eluent (S38AA long fragment fraction) and the supernatant (S38AA short fragment fraction) obtained is quantified by total ELISA. Quantification is carried out according to the method described in Example 4. The calibration curve of each ELISA was created by measuring the S38AA long fragment standard protein. As a result, the quantitative values of the S38AA long fragment and the S38AA short fragment in each sample were obtained ( Fig.10 ). The results showed that the amount of S38AA short fragments in AD patients was significantly increased compared with S38AA long fragments.
[0490] Example 7: Comparison of AD diagnostic performance by quantification of each S38AA fragment (total ELISA-long ELISA subtraction)
[0491] To compare AD diagnostic performance by quantifying each S38AA fragment, ELISA quantification was performed using the subtraction method.
[0492] Specifically, total ELISA and long ELISA were used to quantify the amount of S38AA short fragments and the amount of S38AA long fragments contained in each plasma from 10 healthy subjects and 10 mild AD patients. Quantification was performed according to the method described in Example 4. A calibration curve for each ELISA was created by measuring the S38AA long fragment standard protein. The amount of S38AA short fragments was calculated by subtracting the quantitative value of the long ELISA from the quantitative value of the total ELISA. As a result, the quantitative values of the S38AA long fragments and the S38AA short fragments in each sample were obtained ( Fig.11 In addition, it was shown that mild AD can be diagnosed with high sensitivity by quantifying only the amount of the S38AA short fragment compared with the total amount or the amount of the S38AA long fragment ( Fig.12 ).
[0493] Example 8: Quantification of S38AA fragment in human plasma by combining various anti-S38AA fragment antibodies - 1
[0494] In order to quantify the total amount of the "short S38AA fragment amount" and the "long S38AA fragment amount" contained in human plasma, ELISA quantification was performed using a combination of various anti-S38AA fragment antibodies.
[0495] Specifically, each plasma derived from 4 healthy subjects and 8 AD patients was quantified by "ELISA (mode 1, 2 or 3) using an antibody consisting of a combination of two of Antibody A, Antibody B and Antibody C". Quantification was performed according to the method described in Example 4. A calibration curve for each ELISA was created by measuring the S38AA long fragment standard protein, and a quantitative value ( Fig.14 ).
[0496] Mode 1: ELISA using Antibody A and Antibody B
[0497] Mode 2: ELISA using Antibody A and Antibody C
[0498] Mode 3: ELISA using Antibody B and Antibody C
[0499] As a result of the assay, the measured value of the "sum of the "amount of the S38AA short fragment" and the "amount of the S38AA long fragment"" was equal in each sample, and consistent quantification was obtained regardless of the combination of antibodies used.
[0500] Example 9: Quantification of S38AA fragment in human plasma by combining various anti-S38AA fragment antibodies - 2
[0501] In order to quantify the amount of the "S38AA long fragment" contained in human plasma, ELISA quantification was performed using a combination of various anti-S38AA fragment antibodies.
[0502] Specifically, each plasma derived from 4 healthy subjects and 8 AD patients was quantified by "ELISA (mode 4, 5 or 6) using a combination of one of which is an antibody for long fragments and the other is one of antibody A, antibody B and antibody C". Quantification was performed according to the method described in Example 4. A calibration curve for each ELISA was created by measuring the S38AA long fragment standard protein, and the quantitative value of each sample was obtained ( Fig.15 ).
[0503] Mode 4: ELISA using antibodies for long fragments and Antibody A
[0504] Mode 5: ELISA using antibody for long fragments and antibody B
[0505] Mode 6: ELISA using antibodies for long fragments and Antibody C
[0506] As a result of the measurement, the measured value of "the amount of the S38AA long fragment" was equal in each sample, and consistent quantification was obtained regardless of the combination of antibodies used.
[0507] Example 10: Quantification of S38AA short fragments in human plasma using the results of Examples 8 and 9
[0508] The "amount of the S38AA short fragment" was determined by subtracting the "amount of the S38AA long fragment" obtained in Example 9 from the "sum of the "amount of the S38AA short fragment" and the "amount of the S38AA long fragment" obtained in Example 8" ( Fig.16 ).
[0509] Specifically, subtraction is performed in the following combinations.
[0510] Mode 1-4: Result obtained by subtracting "measurement result of mode 4" from "measurement result of mode 1"
[0511] Mode 1-5: Result obtained by subtracting "measurement result of mode 5" from "measurement result of mode 1"
[0512] Mode 1-6: Result obtained by subtracting "measurement result of mode 6" from "measurement result of mode 1"
[0513] Mode 2-4: Result obtained by subtracting "measurement result of mode 4" from "measurement result of mode 2"
[0514] Mode 2-5: Result obtained by subtracting "measurement result of mode 5" from "measurement result of mode 2"
[0515] Mode 2-6: Result obtained by subtracting "measurement result of mode 6" from "measurement result of mode 2"
[0516] Mode 3-4: Result obtained by subtracting "measurement result of mode 4" from "measurement result of mode 3"
[0517] Mode 3-5: Result obtained by subtracting "measurement result of mode 5" from "measurement result of mode 3"
[0518] Mode 3-6: Result obtained by subtracting "measurement result of mode 6" from "measurement result of mode 3"
[0519] The "amount of the S38AA short fragment" obtained by subtraction showed consistent quantification regardless of the combination of antibodies used.
[0520] This application is based on patent application No. 2018-148924 filed in Japan (filing date: August 7, 2018), the contents of which are incorporated herein in their entirety.
[0521] [Industrial Applicability]
[0522] The present invention can be used for diagnosis and treatment of Alzheimer's disease, etc.
Claims
1. An antibody that specifically recognizes a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1, The antibody is: (1) an antibody comprising a heavy chain variable region of SEQ ID NO: 4 and a light chain variable region of SEQ ID NO: 5, (2) an antibody comprising a heavy chain variable region of SEQ ID NO: 6 and a light chain variable region of SEQ ID NO: 7, (3) an antibody comprising a heavy chain variable region of SEQ ID NO: 8 and a light chain variable region of SEQ ID NO: 9, (4) an antibody comprising a heavy chain variable region of SEQ ID NO: 10 and a light chain variable region of SEQ ID NO: 11, (5) an antibody comprising a heavy chain variable region of SEQ ID NO: 12 and a light chain variable region of SEQ ID NO: 13, (6) an antibody comprising a heavy chain variable region of SEQ ID NO: 14 and a light chain variable region of SEQ ID NO: 15, (7) an antibody comprising a heavy chain variable region of SEQ ID NO: 16 and a light chain variable region of SEQ ID NO: 17, (8) an antibody comprising a heavy chain variable region of SEQ ID NO: 18 and a light chain variable region of SEQ ID NO: 19, (9) an antibody comprising a heavy chain variable region of SEQ ID NO: 20 and a light chain variable region of SEQ ID NO: 21, or (10) An antibody comprising the heavy chain variable region of SEQ ID NO: 22 and the light chain variable region of SEQ ID NO:
23.
2. The antibody according to claim 1, which further recognizes the polypeptide of SEQ ID NO:
2.
3. A method for detecting a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1, comprising the step of contacting a test sample with the antibody according to claim 1 or 2. A kit comprising the antibody according to claim 1 or 2. The kit according to claim 4 , further comprising a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:
1.
6. The kit according to claim 4, which is used for determining whether a test subject suffers from Alzheimer's disease or whether the subject has a high possibility of suffering from Alzheimer's disease in the near future.
7. A reagent for determining Alzheimer's disease or Alzheimer's disease progression in a subject, comprising the antibody of claim 1 or 2.
8. Use of the antibody according to claim 1 or 2 in the preparation of a reagent for determining Alzheimer's disease.
9. A method for screening candidate substances for a therapeutic or preventive drug for Alzheimer's disease, comprising using as an indicator: a decrease in the amount of a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1 in the body of an Alzheimer's disease patient or a person who may suffer from Alzheimer's disease, or an inhibition of the production of the polypeptide in the body of an Alzheimer's disease patient or a person who may suffer from Alzheimer's disease, The polypeptide is detected using the antibody of claim 1 or 2.
